Gallbladder Cancer
Gallbladder cancer is a rare, aggressive malignancy arising most commonly from the glandular epithelium of the gallbladder wall, often associated with gallstones and typically presenting at an advanced stage due to its insidious clinical course.
Gallbladder cancer (GBC) is a primary malignancy arising from the gallbladder wall, most commonly adenocarcinoma (~90%). The name itself tells you everything: "gall" = bile, "bladder" = a hollow sac — so it's cancer of the bile-storage sac.
It is an uncommon but highly lethal malignancy because it tends to present late, often discovered incidentally during cholecystectomy for presumed benign gallstone disease. By the time symptoms appear, the cancer has usually already spread. [1][2]
Why is GBC so deadly?
The gallbladder wall lacks a submucosa (unlike the intestine), meaning there is less tissue barrier between the mucosa and the muscularis. Once the tumour breaches the thin muscular layer, it quickly reaches the subserosal lymphatics and the liver bed (segments IVb and V), which are literally millimetres away. Additionally, the venous drainage goes directly into the liver, providing a highway for haematogenous spread. This anatomical "shortcut" explains why ~75% of patients have regional or distant disease at diagnosis. [1]
Key statistics at presentation [1]:
- 25% localized to gallbladder wall
- 35% have regional nodal involvement or extension into adjacent liver
- 40% have distant metastasis
Epidemiology
- GBC is the most common biliary tract malignancy and the 5th most common GI malignancy worldwide
- Incidence varies dramatically by geography and ethnicity:
- High incidence regions: Chile, Bolivia, northern India, Pakistan, Japan, Korea, Eastern Europe (particularly among indigenous populations)
- Low incidence regions: Western Europe, North America, Australia
- Very rare in Hong Kong [2]
- Female predominance with M:F ratio of approximately 1:2–3 [1][2]
- Why? Women have a higher prevalence of gallstones (estrogen increases cholesterol secretion into bile → cholesterol supersaturation → stone formation). Since gallstones are the strongest risk factor, the female predominance follows logically.
- Peak incidence in the 6th–7th decade of life
- 5-year overall survival < 5% with a median survival of ~6 months for all comers [1][2]
- GBC is uncommon in Hong Kong relative to HCC and colorectal cancer
- However, given the relatively high prevalence of gallstones in the ageing population and the endemic presence of Clonorchis sinensis (liver fluke) in southern China, awareness is important
- Most cases are discovered late and are unresectable at diagnosis [2]
High Yield – Epidemiology
Remember: Female, Fat, Fertile, Forty, Family history (the "5 Fs" of gallstones) → gallstones are the #1 risk factor for GBC → hence GBC has a female predominance. This is a common exam question trap: students forget that GBC risk factors overlap heavily with gallstone risk factors.
Anatomy and Function
Understanding GBC requires a thorough understanding of gallbladder anatomy because the pattern of tumour spread is dictated entirely by the anatomy.
The gallbladder is a pear-shaped, hollow viscus located on the inferior surface of the liver, sitting in the gallbladder fossa between hepatic segments IVb and V.
It is divided into:
| Segment | Description | Clinical Relevance |
|---|---|---|
| Fundus | The rounded, blind-ended tip projecting beyond the liver margin | Associated with the anterior abdominal wall (palpable when distended) and hepatic flexure of colon |
| Body | The main portion | Superiorly: attached to the liver (segments IVb, V) by loose connective tissue. Inferiorly: abuts the duodenum and transverse colon — explaining direct tumour invasion into these structures |
| Infundibulum (Hartmann's pouch) | A small out-pouching at the junction of the body and neck | Common site for gallstone impaction |
| Neck | The narrow tapered portion connecting to the cystic duct | Contains spiral valves of Heister; leads into the cystic duct |
The gallbladder wall is composed of (from lumen outward):
- Mucosa (columnar epithelium + lamina propria)
- Muscularis propria (smooth muscle — single, thin layer)
- Perimuscular connective tissue (also called subserosa/adventitia)
- Serosa (visceral peritoneum) — only on the peritoneal side (the side facing away from the liver)
Critical Anatomical Point
The gallbladder wall LACKS a true submucosa and has only a single thin muscular layer (unlike the intestine which has submucosa, inner circular and outer longitudinal muscle layers, plus a submucosal plexus). This means:
- Lymphatics are present only in the subserosal layer — so cancer confined within the muscularis (T1a, T1b) has minimal risk of nodal disease
- Once it penetrates through the muscularis into the subserosa, lymphatic and haematogenous spread becomes very likely
- The hepatic side of the gallbladder has NO serosa — just connective tissue directly abutting the liver parenchyma, making direct hepatic invasion extremely easy [1]
Arterial supply:
- Cystic artery — branch of the right hepatic artery (found in Calot's triangle)
Venous drainage:
- Cystic veins → drain directly into the gallbladder fossa (liver segments IVb and V) via small veins that traverse the gallbladder bed into the right hepatic vein
- This is why direct venous tumour invasion into the liver (segments IVb and V) is so common — the venous blood literally flows from gallbladder straight into these segments
Lymphatic drainage (follows a predictable, stepwise pattern):
- Cystic duct node (node of Calot/Lund) — first echelon
- Pericholedochal and hilar nodes — second echelon
- Peripancreatic, periduodenal, periportal nodes — third echelon
- Celiac and superior mesenteric artery (SMA) nodes — considered distant (not locoregional), hence incurable by surgery [1]
Nerve supply:
- Sympathetic innervation from the T9 segment and the celiac plexus
- This explains referred pain to the epigastrium and right shoulder (phrenic nerve via diaphragmatic irritation)
- Storage and concentration of bile produced by the liver
- Bile is released into the duodenum via the cystic duct → common bile duct → ampulla of Vater
- Cholecystokinin (CCK) — released from duodenal I-cells in response to fat and amino acids in the duodenum — is the major hormone that stimulates gallbladder contraction and pancreatic enzyme secretion
- Bile contains bile salts, cholesterol, phospholipids, and bilirubin; it emulsifies dietary fat for absorption
Understanding the anatomy makes the spread patterns intuitive:
Sites of distant metastasis: lung, pleura, and peritoneum [1]
Etiology and Risk Factors
The etiology of GBC revolves around chronic inflammation → dysplasia → carcinoma sequence, analogous to the adenoma-carcinoma sequence in colorectal cancer but driven predominantly by chronic biliary irritation.
- Polyps
- Porcelain gallbladder (and other gallstone diseases)
- Primary sclerosing cholangitis
- Pancreatobiliary duct anomalous junction
Below is an expanded and comprehensive discussion of each risk factor:
- 95% of patients with GBC have gallstones [1]
- Larger stones (> 3 cm) and symptomatic gallstones carry higher risk
- Stones > 3 cm have a ~10× increased risk compared to stones < 1 cm
- Pathophysiology: Chronic mechanical irritation of the gallbladder mucosa by gallstones → chronic inflammation → mucosal hyperplasia → metaplasia → dysplasia → carcinoma
- However, the absolute risk of GBC in patients with gallstones remains low (~0.3–0.5% over a lifetime), so prophylactic cholecystectomy for all patients with gallstones is NOT indicated [3]
High Yield: The association between gallstones and GBC is strong but the absolute risk is low. This is why we do NOT recommend prophylactic cholecystectomy for asymptomatic gallstones UNLESS other risk factors are present (e.g., porcelain gallbladder, large stones > 3 cm, polyps > 1 cm).
Gallbladder polyps are classified as:
A. Benign Non-neoplastic (no malignant potential):
- Cholesterol polyps (cholesterolosis) — ~60% of all polyps [1]
- Deposits of cholesterol esters in the submucosal macrophages
- Usually small (< 10 mm), pedunculated, multiple
- Adenomyomatosis (adenomyoma) — ~25% [1]
- Characterized by intramural diverticula called Rokitansky-Aschoff sinuses [2]
- Hypertrophy of the muscularis with invagination of mucosa
- Inflammatory polyps — ~10% [1]
- Granulation tissue from chronic cholecystitis
B. Benign Neoplastic (premalignant potential):
- Adenoma — ~4% [1]
- True neoplasm with malignant potential (like colonic adenomas)
- Risk of malignant transformation increases with size
- Leiomyoma, Fibroma, Lipoma — rare
C. Malignant:
- Adenocarcinoma — ~80% of malignant polyps [1]
- Squamous cell carcinoma, mucinous cystadenoma, adenoacanthoma — rare
Risk stratification by size [1]:
| Polyp Size | Risk of Malignancy | Management |
|---|---|---|
| < 1 cm | < 5% | Regular USG surveillance (Q6mo if 6–9 mm, Q12mo if ≤ 5 mm) [2] |
| 1–1.5 cm | ~46% | Cholecystectomy indicated |
| ≥ 1.5 cm | ~70% | Cholecystectomy indicated; may need extended cholecystectomy with LN dissection [2] |
Key features suggesting malignancy in polyps [1][2]:
- Sessile (broad-based) morphology — malignant polyps tend to be sessile
- Echogenic on USG
- Solitary
- Rapidly growing on serial imaging
- No gravity dependence and no acoustic shadow (differentiating from gallstones on USG) [2]
Polyp vs Stone on USG
A gallstone will be gravity-dependent (moves with patient repositioning), has a posterior acoustic shadow, and is usually echogenic. A polyp is fixed to the wall (does NOT move with repositioning), has no acoustic shadow, and may be echogenic. This distinction is commonly tested. [2]
Indications for cholecystectomy for gallbladder polyps [2]:
- An uncommon manifestation of chronic cholecystitis characterized by intramural calcification of the gallbladder wall
- "Porcelain" → because the calcified wall appears bluish-white and brittle, resembling porcelain
- Associated with gallstones and chronic gallbladder inflammation [1]
- Historically thought to carry a very high malignancy risk (up to 25%), but more recent data suggests the risk is lower (~2–3%), particularly with selective mucosal calcification (which carries higher risk than complete intramural calcification) [2]
- Subtypes [2]:
- Complete intramural calcification — lower malignancy risk
- Selective mucosal calcification — higher malignancy risk (because incomplete calcification suggests ongoing active inflammation)
- ALL porcelain gallbladders should be removed even if patients are asymptomatic — this is an absolute indication for cholecystectomy [1][3]
- An autoimmune inflammatory disorder of the biliary tree leading to fibrosis and stricturing of intrahepatic and extrahepatic bile ducts
- Strongly associated with ulcerative colitis [4]
- Chronic inflammation and biliary stasis → increased risk of both cholangiocarcinoma and GBC
- Patients with PSC should have a lower threshold for cholecystectomy when polyps are found (≥ 8 mm rather than the usual 1 cm cutoff) [2]
- A rare congenital anatomical variation in which the pancreatic duct joins the common bile duct outside the duodenal wall, creating an abnormally long common channel (> 15 mm)
- Associated with choledochal cysts [2]
- Pathophysiology: The sphincter of Oddi cannot regulate the long common channel → reflux of pancreatic juice into the biliary tree → chronic chemical inflammation from activated pancreatic enzymes → mucosal injury → metaplasia → dysplasia → carcinoma
- Represents failure of the embryological ducts to migrate fully into the duodenum [1]
- GBC is the most common malignancy associated with APBDJ
- Prophylactic cholecystectomy is recommended [1]
- Congenital cystic dilatation of the bile ducts
- Most diagnosed before 10 years of age (60%) [2]
- Classified by the Todani classification (most commonly Type I) [2]
- Risk of cholangiocarcinoma and GBC via:
- Biliary stasis
- Chronic inflammation from reflux of pancreatic juice
- Abnormalities in bile salt transporter proteins
- Management: Radical excision of cyst + biliary tract reconstruction using a Roux-en-Y loop of jejunum (hepaticojejunostomy) — to prevent development of cholangiocarcinoma [2]
- Common hepatic duct obstruction caused by extrinsic compression from an impacted stone in the cystic duct or Hartmann's pouch [1][5]
- Chronic inflammation and biliary stasis → predisposes to GBC [5]
- One of the exceptions to Courvoisier's Law (jaundice with palpable gallbladder due to a benign cause) [5]
- Result of recurrent acute cholecystitis or persistent mechanical irritation by gallstones → fibrosis and thickening of GB wall
- The dysplasia-carcinoma sequence in GBC is thought to parallel the chronic inflammation → metaplasia → dysplasia → carcinoma pathway seen in Barrett's oesophagus and other chronic inflammatory conditions
- Chronic cholecystitis is associated with CA gallbladder and porcelain gallbladder [6]
| Risk Factor | Mechanism |
|---|---|
| Obesity | Increased cholesterol in bile → more gallstones → chronic inflammation |
| Diabetes mellitus | Gallbladder dysmotility + gallstone risk |
| Female sex / Multiparity | Estrogen → increased biliary cholesterol secretion → stones |
| Clonorchis sinensis / Opisthorchis infection | Liver flukes inhabit biliary tree → chronic inflammation → malignant transformation (relevant in Hong Kong/South China) [7] |
| Smoking | Carcinogens excreted in bile |
| Family history | Genetic predisposition (rare familial clustering reported) |
| Typhoid carrier state | Chronic Salmonella typhi colonization of gallbladder → chronic inflammation [6] |
Pathophysiology
The dominant paradigm for GBC carcinogenesis is:
This sequence takes 15–20 years on average, explaining why GBC typically presents in the 6th–7th decade.
A smaller proportion of GBCs (~5–10%) arise from pre-existing adenomatous polyps through the traditional adenoma → carcinoma pathway (similar to colorectal cancer). This is less common but explains why adenomatous polyps > 1 cm should be removed.
- p53 mutations — common in GBC; tumour suppressor gene on chromosome 17p
- KRAS mutations — oncogene activation; more common in the setting of APBDJ
- CDKN2A/p16 inactivation — cell cycle checkpoint loss
- Microsatellite instability (MSI) — found in a subset, relevant for immunotherapy
- ERBB2 (HER2) amplification — potential therapeutic target
- PI3K/AKT/mTOR pathway activation
- EGFR overexpression
Classification
| Type | Frequency | Notes |
|---|---|---|
| Adenocarcinoma | ~90% | Most common; subtypes: papillary, nodular, tubular |
| Squamous cell carcinoma | Rare | |
| Mucinous cystadenoma | Rare | |
| Adenoacanthoma | Rare | Mixed glandular + squamous |
| Adenosquamous | Rare | |
| Small cell / neuroendocrine | Very rare |
Adenocarcinoma subtypes [1]:
- Papillary — bulky, intraluminal growth; associated with the most favourable outcome because it tends to grow into the lumen rather than invading the wall early
- Nodular — constricting, annular pattern
- Tubular — glandular pattern; most common subtype
Primary Tumour (T):
| Stage | Description |
|---|---|
| Tis | Carcinoma in situ |
| T1a | Tumour invades the lamina propria |
| T1b | Tumour invades the muscular layer |
| T2a | Tumour invades perimuscular connective tissue on the peritoneal side (without serosal involvement) |
| T2b | Tumour invades perimuscular connective tissue on the hepatic side (without liver extension) |
| T3 | Tumour perforates serosa AND/OR directly invades liver and/or one other adjacent organ (stomach, duodenum, colon, pancreas, omentum, extrahepatic bile ducts) |
| T4 | Tumour invades main portal vein or hepatic artery OR invades ≥ 2 extrahepatic organs |
T2a vs T2b — Why does it matter?
This distinction is unique to gallbladder cancer and reflects the asymmetric anatomy:
- T2a (peritoneal side): The peritoneal surface has a serosa — tumour must penetrate the serosa to spread into the peritoneal cavity. These tumours have a slightly better prognosis.
- T2b (hepatic side): There is NO serosa on the hepatic side — only loose connective tissue separating the gallbladder from the liver. Tumour on this side has a more direct route to invade the liver. T2b generally has a worse prognosis than T2a.
Regional Lymph Nodes (N):
| Stage | Description |
|---|---|
| N0 | No regional lymph node metastasis |
| N1 | Metastasis to 1–3 regional lymph nodes |
| N2 | Metastasis to ≥ 4 regional lymph nodes |
Distant Metastasis (M):
| Stage | Description |
|---|---|
| M0 | No distant metastasis |
| M1 | Distant metastasis |
Overall Stage Grouping:
| Stage | T | N | M |
|---|---|---|---|
| 0 | Tis | N0 | M0 |
| I | T1 | N0 | M0 |
| IIA | T2a | N0 | M0 |
| IIB | T2b | N0 | M0 |
| IIIA | T3 | N0 | M0 |
| IIIB | T1–3 | N1 | M0 |
| IVA | T4 | N0–1 | M0 |
| IVB | Any T | N2 | M0 |
| IVB | Any T | Any N | M1 |
High Yield: T1a (lamina propria only) → simple cholecystectomy is curative. T1b and beyond → extended cholecystectomy with lymph node dissection is needed. This staging-to-surgery mapping is commonly tested.
Clinical Features
GBC is notoriously difficult to diagnose early because its symptoms mimic benign gallbladder disease [2]. Most patients present with symptoms attributable to coexisting gallstones rather than the cancer itself.
| Symptom | Pathophysiological Basis | Stage |
|---|---|---|
| RUQ pain / biliary colic | Due to coexisting gallstones (present in 95% of GBC patients) rather than the cancer itself. Gallstone impaction → cystic duct obstruction → visceral pain via T9 sympathetic afferents [1][2] | Early |
| Epigastric discomfort | Visceral pain from gallbladder distension; may mimic dyspepsia or peptic ulcer disease | Early |
| Nausea and vomiting | Vagal stimulation from gallbladder inflammation; or duodenal involvement causing gastric outlet obstruction | Early/Late |
| Obstructive jaundice (painless or painful) | Late feature indicating tumour invasion or compression of the extrahepatic bile ducts (CBD/CHD) or metastatic lymph nodes at the porta hepatis compressing the bile duct. Conjugated bilirubin cannot reach the duodenum → refluxes back into blood [2][8] | Late |
| Dark urine (tea/cola-coloured) | Conjugated (water-soluble) bilirubin spills into blood → excreted by kidneys → dark urine (choluria) | Late |
| Pale/clay-coloured stools (acholic) | No bilirubin reaching the duodenum → no stercobilinogen production → pale stools | Late |
| Pruritus | Bile salt deposition in the skin due to cholestasis. Bile salts are normally excreted in bile; when obstructed, they accumulate in blood and deposit in skin, stimulating nerve endings | Late |
| Weight loss and anorexia (constitutional symptoms) | Cancer cachexia: tumour-derived cytokines (TNF-α, IL-6) → systemic inflammation → increased metabolic rate + decreased appetite. Also, fat malabsorption from bile duct obstruction contributes | Late |
| Malaise and fatigue | Anaemia of chronic disease; cancer cachexia; malabsorption | Late |
Early Symptoms are Indistinguishable from Gallstone Disease
Early stage GBC presents with biliary colic and RUQ pain — symptoms attributable to gallstones rather than the cancer itself [2]. This is why most GBC is diagnosed incidentally at cholecystectomy or at an advanced stage when obstructive jaundice or a mass develops. The cancer doesn't produce unique early warning symptoms — it hides behind its most common co-morbidity (gallstones).
| Sign | Pathophysiological Basis | Notes |
|---|---|---|
| Palpable RUQ mass / Hepatomegaly | Direct tumour extension into the liver (segments IVb, V) or a distended gallbladder (if the cystic duct is not chronically fibrosed) [2] | Late finding; hard, irregular, non-tender |
| Jaundice (scleral icterus) | Bilirubin > 35 µmol/L → visible yellow discoloration of sclera (sclera has high elastin content with affinity for bilirubin) [8] | Indicates biliary obstruction |
| Palpable gallbladder (Courvoisier's sign) | If the gallbladder wall is NOT fibrosed (i.e., no chronic cholecystitis), the gallbladder can distend proximal to a distal biliary obstruction. In GBC with CBD involvement, if the obstruction is distal to the cystic duct insertion AND the gallbladder wall is still compliant → palpable, non-tender gallbladder [8] | However, most GBC patients have concurrent gallstones → chronic cholecystitis → fibrosed, non-distensible gallbladder → Courvoisier's sign is often ABSENT |
| Murphy's sign | Inspiratory arrest during deep RUQ palpation — indicates acute cholecystitis (parietal peritoneal inflammation) from concurrent gallstone disease | Non-specific |
| Ascites | Peritoneal carcinomatosis (tumour seedlings on peritoneal surfaces) → exudative ascites; or portal vein invasion → portal hypertension → transudative ascites | Late; poor prognostic sign |
| Sister Mary Joseph nodule | Periumbilical subcutaneous metastatic nodule — tumour spread via peritoneal ligaments (falciform ligament) or lymphatics to the umbilicus | Rare but classic sign of intra-abdominal malignancy |
| Virchow's node (left supraclavicular lymphadenopathy) | Metastatic spread via thoracic duct to the left supraclavicular fossa | Indicates disseminated disease |
| Hepatomegaly (irregular, hard) | Direct liver invasion or intrahepatic metastases | May be nodular on palpation |
| Cachexia | Advanced disease with cytokine-mediated muscle wasting |
"In the presence of painless obstructive jaundice, a palpable gallbladder is unlikely to be due to gallstones" — Courvoisier
Why? A gallbladder that has been chronically inflamed by gallstones becomes fibrosed and shrunken — it cannot distend. Therefore, if you find painless jaundice + a distended, palpable gallbladder, think of a malignant cause of distal biliary obstruction (e.g., pancreatic head cancer, ampullary cancer, distal cholangiocarcinoma) [8].
In GBC specifically: Despite being a malignancy, GBC often does NOT produce a palpable gallbladder because:
- The cancer arises FROM the gallbladder wall → the wall is rigid and infiltrated → cannot distend
- Coexisting gallstones → chronic cholecystitis → fibrosed wall
Exceptions to Courvoisier's Law (jaundice with palpable gallbladder from benign causes) [5]:
- Double impaction (gallstone in cystic duct + CBD simultaneously)
- Mirizzi syndrome [5]
- Recurrent pyogenic cholangitis (RPC)
Painless Jaundice + Epigastric Mass
This is a classic exam presentation [8]. The differential includes:
- Pancreatic head cancer (most common cause of painless obstructive jaundice + palpable gallbladder)
- Ampullary / periampullary tumour
- Distal cholangiocarcinoma
- Gallbladder cancer (less commonly causes a palpable gallbladder due to concurrent fibrosis)
The lecture WCS 056 focuses on this presentation — always think malignancy first. [8]
- A significant proportion of GBC is found incidentally during or after cholecystectomy for presumed benign disease
- The surgeon may notice:
- An abnormal gallbladder wall (thickened, mass-like)
- Suspicious findings on frozen section of the cystic duct margin
- Unexpected pathology report showing carcinoma in the cholecystectomy specimen
- Intraoperative frozen section of the cystic duct is critical — a positive margin mandates further surgery [1]
| Fundus/Body | Neck/Cystic duct |
|---|---|
| Tends to present later (grows away from bile ducts) | Presents earlier with obstructive jaundice (closer to biliary confluence) |
| More likely to invade liver directly | More likely to obstruct CBD |
| Often presents as incidental finding or mass | May mimic Mirizzi syndrome |
GBC does not commonly produce paraneoplastic syndromes (unlike HCC), but when present:
- Trousseau syndrome (migratory thrombophlebitis) — mucin-producing adenocarcinomas can activate the coagulation cascade
- Leser-Trélat sign — explosive onset of seborrhoeic keratoses (rare, non-specific)
| Anatomical Feature | Clinical Consequence |
|---|---|
| Lack of submucosa | Rapid transmural invasion |
| Thin single muscular layer | Minimal barrier to spread |
| No serosa on hepatic side | Direct liver invasion (Seg IVb, V) |
| Venous drainage into liver | Haematogenous liver metastasis |
| Lymphatics only in subserosa | T1a/b = minimal nodal risk; T2+ = significant nodal risk |
| Close proximity to duodenum, colon, stomach | Direct invasion into GI structures |
| Lymphatic chain → celiac/SMA nodes | Distant nodal disease = incurable |
High Yield Summary
Definition: Primary malignancy of the gallbladder, ~90% adenocarcinoma, uncommon but highly fatal.
Epidemiology: Female predominance (M:F 1:2–3), peak 6th–7th decade, very rare in HK, 5-year OS < 5%, 75% have regional/distant disease at diagnosis.
Anatomy: GB sits on segments IVb/V; lacks submucosa; thin muscularis; NO serosa on hepatic side → explains rapid liver invasion. Venous drainage directly into liver. Lymphatics: cystic node → pericholedochal → hilar → peripancreatic → celiac/SMA.
Risk Factors (4P + Stones): Gallstones (95% of GBC patients), Polyps (> 1cm), Porcelain gallbladder, PSC, Pancreatobiliary duct anomaly; also chronic cholecystitis, Mirizzi syndrome, choledochal cysts, obesity, DM, Clonorchis sinensis.
Pathophysiology: Chronic inflammation → hyperplasia → metaplasia → dysplasia → carcinoma (15–20 year sequence).
Clinical Features:
- Early: Biliary colic, RUQ pain (mimics gallstones — GBC hides behind gallstone symptoms)
- Late: Obstructive jaundice, palpable mass, constitutional symptoms (LOW/LOA), dark urine, pale stools, pruritus, ascites
- Most GBC diagnosed incidentally at cholecystectomy or at advanced stage
TNM Key Points: T1a = lamina propria; T1b = muscularis; T2a = peritoneal side; T2b = hepatic side (worse); T3 = serosa/liver/adjacent organs; T4 = major vessels/≥2 organs. N1 = 1–3 nodes; N2 = ≥4 nodes.
Active Recall - Gallbladder Cancer (Definition to Clinical Features)
[1] Senior notes: felixlai.md (Gallbladder cancer section, pages 563–571) [2] Senior notes: maxim.md (Section 5.7 — Cancers of gallbladder and biliary tree) [3] Senior notes: maxim.md (Cholecystectomy indications section) [4] Senior notes: felixlai.md (Cholangiocarcinoma etiology section, page 548) [5] Senior notes: maxim.md (Mirizzi syndrome section, pages 131–132) and felixlai.md (Mirizzi syndrome section, pages 572–573) [6] Senior notes: maxim.md (Chronic cholecystitis section, page 130) [7] Senior notes: maxim.md (Clonorchis sinensis section, page 138) [8] Lecture slides: WCS 056 - Painless jaundice and epigastric mass - by Prof R Poon.ppt (1).pdf
Differential Diagnosis of Gallbladder Cancer
Before diving into the list, let's understand why the differential is broad and clinically important. GBC presents in two fundamentally different clinical scenarios, and the differential changes depending on the presentation:
- Early presentation — biliary colic, RUQ pain → indistinguishable from benign gallstone disease (GBC is found in 95% of patients with concurrent gallstones) [1][2]
- Late presentation — obstructive jaundice, palpable mass, constitutional symptoms → overlaps with all causes of malignant biliary obstruction (MBO) [8][9]
The differential must therefore be structured around these two clinical presentations, and additionally around the level of biliary obstruction seen on imaging.
Structured Differential Diagnosis
These are conditions that mimic the gallstone-like presentation of early GBC:
| Differential | Key Distinguishing Features | Why It Mimics GBC |
|---|---|---|
| Acute cholecystitis | Prolonged RUQ pain > 6 hrs, fever, positive Murphy's sign, leukocytosis; USG shows wall thickening + pericholecystic fluid + stones [3] | Both present with RUQ pain + gallstones; GBC may coexist with acute cholecystitis |
| Chronic cholecystitis | Recurrent biliary colic attacks; USG shows contracted, thick-walled gallbladder with stones [6] | GBC arises on a background of chronic cholecystitis; histologically may only be distinguishable on final pathology |
| Gallbladder polyps (benign) | Asymptomatic or biliary colic; USG shows fixed echogenic lesion without acoustic shadow, no gravity dependence [2] | Cannot reliably distinguish benign polyp from early polypoid GBC on imaging alone — this is why polyps ≥ 1 cm need cholecystectomy |
| Cholelithiasis (symptomatic gallstones without cancer) | Intermittent biliary colic < 6 hrs; USG shows mobile, gravity-dependent stones with acoustic shadow [3] | 95% of GBC patients have gallstones — the symptoms are from stones, not the cancer itself |
| Mirizzi syndrome | CHD obstruction from stone impacted in Hartmann's pouch/cystic duct; jaundice + RUQ pain; MRCP/ERCP shows extrinsic compression of CHD [5] | Can present identically to GBC at the neck/cystic duct; chronic inflammation from Mirizzi itself predisposes to GBC |
| Xanthogranulomatous cholecystitis | A destructive inflammatory condition of GB wall mimicking GBC on imaging; thick, irregular wall with intramural nodules; diagnosis often made only on histopathology | Radiologically very difficult to differentiate from GBC — both show irregular wall thickening, loss of fat planes with liver, and local lymphadenopathy |
| Gallbladder empyema | Fever, sepsis, tender RUQ mass; USG shows distended GB with echogenic debris | A palpable, tender GB mass may initially raise concern for GBC |
| Adenomyomatosis | Benign, characterised by Rokitansky-Aschoff sinuses; "comet tail" artefact on USG [2] | Focal adenomyomatosis of the fundus can mimic a mass lesion on USG |
Xanthogranulomatous Cholecystitis — The Great Mimicker
This is a particularly important differential because it is a benign inflammatory condition that can be virtually indistinguishable from GBC on CT and even at surgery. The GB wall is massively thickened, irregular, and may invade the liver bed — exactly like GBC. Even frozen section can be misleading. The definitive diagnosis often requires full histopathological examination showing foamy macrophages (xanthoma cells) and giant cells rather than adenocarcinoma. Keep this in mind when a "GBC" doesn't behave as expected.
This is the more common exam scenario: a patient presents with painless progressive obstructive jaundice — and the question is: what is causing the biliary obstruction?
The differential here overlaps with all causes of malignant biliary obstruction. The lecture slides from Prof R Poon provide a clear framework [8][9]:
Pathology causing malignant biliary obstruction [8]:
- Carcinoma of gallbladder — via cystic duct LN compression, direct infiltration of CBD, or tumour fragments in the duct
- Cholangiocarcinoma (including Klatskin tumour at hilum)
- Carcinoma of head of pancreas
- Periampullary carcinoma (carcinoma of the ampulla of Vater)
- Carcinoma of duodenum
- Lymphoma
- HCC — direct infiltration, compression, or tumour fragments in CBD [8][9]
- Porta lymphadenopathy (metastatic nodes at the porta hepatis compressing the bile duct) [9]
This is a critical concept for imaging interpretation. When you see biliary dilatation on USG or CT, the level at which the ducts transition from dilated to non-dilated tells you where the obstruction is — and narrows the differential dramatically [10]:
| Level of Obstruction | Differentials | Why |
|---|---|---|
| Hilum (intrahepatic ducts dilated, CHD/CBD not dilated below the hilum) | CA gallbladder [10], Klatskin tumour (perihilar cholangiocarcinoma) [10], HCC [10], Mirizzi syndrome [10], Porta lymphadenopathy [9][10], PSC [10], RPC [10] | GBC at the neck can compress the CHD/hilum; Klatskin tumour sits at the confluence; HCC invades or compresses intrahepatic ducts |
| Mid-CBD | CA CBD (cholangiocarcinoma) [10], CA head of pancreas [10], Lymphadenopathy [10] | Tumours at this level compress the mid-CBD externally or grow within its wall |
| Distal CBD | Periampullary carcinoma [10], CA head of pancreas [10], Bile duct strictures [10], Choledochal cysts [10], Chronic pancreatitis [10], Pancreatic cysts [10] | Distal CBD obstruction causes dilatation of the entire biliary tree above + a distended gallbladder (Courvoisier's sign) |
How Does GBC Cause Obstructive Jaundice?
GBC causes biliary obstruction by three distinct mechanisms [8]:
- Cystic duct lymph node enlargement — metastatic nodes compress the CHD/CBD from outside
- Direct infiltration of the CBD — tumour growing from the gallbladder wall directly into the adjacent bile duct
- Tumour fragments — detached tumour fragments falling into the biliary lumen (rare)
This is different from, say, pancreatic head cancer, which compresses the distal CBD from outside. Understanding the mechanism helps you predict the imaging pattern.
While GBC enters the differential for malignant causes, always remember benign causes of obstructive jaundice that can mimic the presentation [7]:
| Benign Cause | Key Distinguishing Features |
|---|---|
| Choledocholithiasis | Colicky pain, fluctuating jaundice (stone moves), USG shows CBD stone + acoustic shadow; painless progressive jaundice suggests malignancy, NOT stones [7] |
| Acute cholangitis | Charcot's triad (fever + jaundice + RUQ pain); Reynolds' pentad adds hypotension + confusion [3] |
| PSC | Young patient + ulcerative colitis; MRCP shows "beading" of intrahepatic/extrahepatic ducts |
| IgG4-related sclerosing cholangitis | Responds to steroids; elevated serum IgG4 |
| Chronic pancreatitis | Calcifications on CT; history of alcohol/recurrent pancreatitis; distal CBD narrowing |
| Choledochal cyst | Usually diagnosed in childhood; MRCP shows cystic dilatation of the bile duct [2] |
High Yield Exam Point: "Painless progressive obstructive jaundice in an elderly patient is malignant biliary obstruction until proven otherwise" [7]. The key word is "progressive" — gallstone jaundice tends to be intermittent and fluctuating (the stone moves), while malignant jaundice is relentlessly progressive (the tumour only grows).
Let's compare the "big five" malignant causes of biliary obstruction side by side — this is extremely high yield for exams [8][9]:
| Feature | GBC | Pancreatic head CA | Cholangiocarcinoma | Periampullary CA | HCC |
|---|---|---|---|---|---|
| Age/Sex | 60–70s, F > M | 60–70s, M > F | > 50, slight M > F | 60–70s | 50–60s, M >> F |
| Background disease | Gallstones (95%) | DM, chronic pancreatitis | PSC, RPC, choledochal cyst | None specific | HBV, HCV, cirrhosis |
| Jaundice pattern | Late; often painful (stones) | Painless, progressive | Painless, progressive (extrahepatic); absent (intrahepatic) | Painless, progressive ± intermittent (tumour necrosis) | Uncommon unless bile duct invasion |
| Courvoisier's sign | Usually absent (fibrosed GB) | Positive (classic) | Positive if distal | Positive | Absent |
| Key tumour marker | CA 19-9, CEA (non-specific) | CA 19-9 | CA 19-9 | None specific | AFP |
| Imaging hallmark | GB wall mass/thickening | Hypoattenuating pancreatic mass; double duct sign | Duct stricture with upstream dilatation | Ampullary mass on CT/endoscopy | Arterially enhancing liver mass |
| Liver involvement | Direct invasion Seg IVb/V | Liver metastases (late) | Intrahepatic mass or hilar stricture | Uncommon | Primary liver mass |
| 5-year survival | < 5% (overall) | ~10% | 5–15% | ~40% (best prognosis among these) | Variable (20–70% if resectable) |
Double Duct Sign
The "double duct sign" refers to simultaneous dilatation of BOTH the pancreatic duct AND the CBD on CT/MRCP. This is classically seen in CA head of pancreas because the tumour sits at the head where both ducts converge. GBC does NOT typically produce a double duct sign because it obstructs the biliary tree at the hilum or mid-CBD level, proximal to the pancreatic duct. Cholangiocarcinoma also typically does not produce a double duct sign unless it is distal.
This is one of the most commonly tested clinical reasoning exercises [7]:
| Feature | Suggests Gallstones (Benign) | Suggests GBC (Malignant) |
|---|---|---|
| Jaundice onset | Acute, fluctuating, may resolve spontaneously (stone passes) | Progressive, unrelenting, worsening over weeks |
| Pain character | Colicky, intermittent (< 6 hrs per episode) | Constant, dull; may have a colicky component from coexisting stones |
| Fever | Common (cholangitis) | Uncommon unless secondary cholangitis from obstruction |
| Weight loss | Absent | Present (cancer cachexia) |
| Stool colour | May fluctuate (stone moves, some bile gets through intermittently) | Persistently pale (complete obstruction) |
| Urine colour | Dark when jaundiced, normalises when stone passes | Persistently dark |
| Palpable GB | Absent (chronic cholecystitis → fibrosed GB) | Usually absent too (same fibrosed GB), but may have a hard, irregular RUQ mass |
| Courvoisier's sign | Usually absent | Usually absent (unlike pancreatic head CA) |
| Age/demographics | Any age, F > M | Elderly, F > M |
| Prior biliary surgery | May have had prior cholecystectomy | Gallstones found in 95% — typically NO prior cholecystectomy |
When imaging reveals a gallbladder wall mass or thickening, the differential includes:
| Diagnosis | Key Features |
|---|---|
| GBC | Irregular wall thickening, loss of GB-liver interface, local LN, enhancing mass |
| Xanthogranulomatous cholecystitis | Can be indistinguishable from GBC; foamy macrophages on histology |
| Gallbladder adenomyomatosis (focal) | Fundal thickening with "comet tail" artefact; Rokitansky-Aschoff sinuses |
| Gallbladder metastasis | Rare; from melanoma, breast, renal cell carcinoma; usually in context of known primary |
| Gallbladder lymphoma | Extremely rare |
| Acute/chronic cholecystitis | Diffuse (not focal) wall thickening; clinical context of pain/fever; resolves with treatment |
High Yield Summary — Differential Diagnosis
Two presentation-based frameworks:
- Early (RUQ pain/biliary colic): DDx is benign gallbladder disease — acute/chronic cholecystitis, cholelithiasis, benign polyps, Mirizzi syndrome, xanthogranulomatous cholecystitis, adenomyomatosis
- Late (obstructive jaundice/mass): DDx is malignant biliary obstruction — CA gallbladder, cholangiocarcinoma (including Klatskin tumour), CA head of pancreas, periampullary CA, CA duodenum, HCC, lymphoma, porta lymphadenopathy [8][9]
Level-based approach [10]: Hilum (GBC, Klatskin, HCC, Mirizzi, porta nodes) → Mid-CBD (cholangioCA, pancreas CA) → Distal CBD (periampullary, pancreatic, choledocholithiasis)
Key distinguishing features: GBC → fibrosed GB (Courvoisier usually negative), coexisting gallstones (95%), GB wall mass/thickening on imaging. Pancreatic CA → painless progressive jaundice + Courvoisier positive + double duct sign. Cholangiocarcinoma → duct stricture + upstream dilatation.
"Painless progressive obstructive jaundice in elderly = malignant until proven otherwise" [7]
Active Recall - Differential Diagnosis of Gallbladder Cancer
References
[1] Senior notes: felixlai.md (Gallbladder cancer section, pages 563–571) [2] Senior notes: maxim.md (Section 5.7 — Cancers of gallbladder and biliary tree; Gallbladder polyps) [3] Senior notes: felixlai.md (Biliary colic differential diagnosis section, page 511) [5] Senior notes: felixlai.md (Mirizzi syndrome section, pages 572–574) [6] Senior notes: maxim.md (Chronic cholecystitis section) [7] Senior notes: maxim.md (Obstructive jaundice section, page 125) [8] Lecture slides: WCS 056 - Painless jaundice and epigastric mass - by Prof R Poon.ppt (1).pdf (p23–24) [9] Lecture slides: Malignant biliary obstruction.pdf (p5) [10] Senior notes: felixlai.md (Malignant biliary obstruction — causes by level of obstruction, page 500)
Diagnostic Criteria and Approach
Unlike some medical conditions (e.g., rheumatoid arthritis with ACR/EULAR criteria, or diabetes with specific glucose thresholds), GBC does not have a standardised set of clinical diagnostic criteria. The diagnosis is ultimately histopathological — you need tissue to confirm adenocarcinoma of the gallbladder.
In practice, GBC is diagnosed in one of three clinical scenarios:
- Incidental discovery — found on histopathology of a cholecystectomy specimen performed for presumed benign disease (most common scenario, ~50–70% of cases) [1][2]
- Preoperative suspicion — clinical features + imaging findings raise suspicion → tissue confirmation sought before definitive surgery
- Advanced/unresectable disease — diagnosed on imaging ± percutaneous/EUS-guided biopsy when the tumour is clearly inoperable
The diagnostic approach therefore centres on: clinical assessment → laboratory investigations → imaging → tissue diagnosis → staging [1][11]
The approach to diagnosing GBC can be divided into two pathways depending on the clinical scenario:
Two Critical Principles in the Diagnostic Algorithm
-
Tissue diagnosis (biopsy) is NOT mandatory before surgery if the tumour appears resectable — because percutaneous biopsy risks tumour seeding along the needle tract and peritoneal dissemination. Biopsy is reserved for unresectable cases where histological confirmation is needed before starting palliative chemotherapy. [1][2][11]
-
Staging laparoscopy should be performed before committing to laparotomy — because GBC frequently has peritoneal or liver metastases that are NOT detectable on preoperative imaging (CT/MRI). Laparoscopy avoids an unnecessary, morbid laparotomy. [1]
Investigation Modalities
A. Physical Examination
Physical examination is the first step and provides crucial information about disease extent and operability.
| Finding | Significance | Pathophysiological Basis |
|---|---|---|
| Jaundice | Biliary obstruction by tumour | Conjugated bilirubin refluxes into blood → deposits in sclera/skin (visible when bilirubin > ~35 µmol/L) |
| Cachexia/wasting | Advanced disease | Tumour-derived cytokines (TNF-α, IL-6) → increased catabolism |
| Pallor | Anaemia of chronic disease | Chronic inflammation suppresses erythropoiesis; also malabsorption of iron/B12 |
| Lymphadenopathy | Metastatic spread | Check left supraclavicular fossa (Troisier's sign / Virchow's node) — distant metastasis via thoracic duct [10] |
| Finding | Significance | How to Elicit |
|---|---|---|
| Hepatomegaly (irregular surface, hard, non-tender) | Direct liver invasion (Seg IVb/V) or intrahepatic metastases | Palpate from RIF upward; assess size, surface, edge, tenderness, consistency; listen for bruit [11] |
| Palpable gallbladder | Assess Courvoisier's law (see below) | Palpate below the right costal margin at the tip of the 9th costal cartilage |
| Scratch marks (pruritus) | Cholestasis → bile salt deposition in skin | Inspect arms, trunk, legs [10] |
| Stigmata of chronic liver disease | Background cirrhosis may indicate HCC rather than GBC | Spider naevi, palmar erythema, gynaecomastia, caput medusae |
| Ascites | Peritoneal metastasis (malignant ascites) or portal vein invasion | Shifting dullness, fluid thrill [10] |
| Sister Mary Joseph nodule | Periumbilical subcutaneous metastasis via peritoneal ligaments | Palpate umbilicus [10] |
| Blumer's shelf | Peritoneal metastasis in rectovesical/rectouterine pouch | DRE — palpable "shelf" anteriorly [10] |
"ALWAYS look for a palpable gallbladder in malignant biliary obstruction" [10]
- Definition: "In painless jaundice if the gallbladder is palpable, it is unlikely to be due to gallstones" — points towards malignant biliary obstruction [1][10]
- Why? Gallstones → chronic cholecystitis → GB wall fibrosed and contracted → cannot distend. Malignant obstruction develops over a shorter time → GB wall is still compliant → distends from back-pressure [1]
- In GBC specifically: Courvoisier's sign is usually ABSENT because the cancer arises in the GB wall itself (rigid) + coexisting gallstones cause chronic fibrosis
- Exceptions [1][10]:
- Double impaction (stone in cystic duct + CBD)
- Recurrent pyogenic cholangitis (RPC) — pathology in bile duct, not GB → no chronic cholecystitis → GB not fibrosed, can distend
- Mirizzi syndrome
These findings at physical examination indicate unresectable/incurable disease — crucial to assess before planning surgery:
| Sign | What It Indicates |
|---|---|
| Irregular surface hepatomegaly | Liver metastases or direct invasion |
| Troisier's sign (Virchow's node) | Distant LN metastasis (left supraclavicular) |
| Blumer's shelf | Peritoneal metastasis (drop metastasis to pouch of Douglas) |
| Sister Mary Joseph nodule | Peritoneal metastasis |
| Ascites | Peritoneal carcinomatosis or portal vein invasion |
B. Laboratory Investigations (Biochemical Tests)
| Finding | Significance | Why |
|---|---|---|
| Leukocytosis | Associated biliary sepsis (cholangitis) | Bacterial infection of stagnant bile proximal to obstruction → systemic inflammatory response |
| Thrombocytopenia | Check before planning invasive procedures (ERCP, biopsy) | Impaired thrombopoietin production in liver disease; also consumptive coagulopathy |
| Anaemia | Chronic disease; possible GI blood loss | Normocytic normochromic anaemia of chronic inflammation; iron deficiency if occult GI bleeding |
| Pancytopenia | If underlying cirrhosis with portal hypertension | Hypersplenism → sequestration of blood cells [10] |
| Finding | Significance | Why |
|---|---|---|
| ↑ PT/INR | Coagulopathy due to Vitamin K deficiency | Obstructive jaundice → no bile salts in the gut → impaired absorption of fat-soluble vitamins (A, D, E, K) → Vitamin K is essential for hepatic synthesis of clotting factors II, VII, IX, X → prolonged PT [1][10] |
Why Check Clotting Before ERCP?
ERCP involves sphincterotomy (cutting the sphincter of Oddi), which can cause significant bleeding. Additionally, percutaneous biopsy and biliary drainage procedures carry haemorrhagic risk. In obstructive jaundice, patients are often coagulopathic from Vitamin K malabsorption. Always correct coagulopathy with parenteral Vitamin K (IV/IM — NOT oral, because oral Vitamin K also requires bile salts for absorption!) before invasive procedures.
| Parameter | Expected Finding | Interpretation |
|---|---|---|
| ↑ Bilirubin (conjugated) | Elevated, progressive | Obstruction → conjugated bilirubin cannot drain into duodenum → refluxes back into blood |
| ↑ ALP | Markedly elevated | ALP is concentrated on the canalicular membrane of hepatocytes. When bile flow is obstructed, bile acids accumulate → solubilise ALP from the membrane → ALP enters the blood. Also, cholestasis induces ALP gene transcription |
| ↑ GGT | Markedly elevated | Elevation of GGT confirms that excess ALP is of hepatobiliary origin (as opposed to bone — important because ALP alone could be from bone metastases) [11] |
| ↑ AST/ALT | May be mildly elevated or normal initially | Transaminases rise when chronic biliary obstruction leads to hepatocyte damage (secondary hepatocellular injury from bile stasis). Initially normal in pure obstructive jaundice [11] |
| ↓ Albumin | In advanced/chronic disease | Impaired hepatic synthetic function; also indicator of nutritional status |
The overall pattern is a cholestatic picture: ↑↑ ALP, ↑↑ GGT, ↑ conjugated bilirubin, with relatively preserved transaminases initially [2][10]
Tumour markers are NOT very useful for MBO as a screening tool and are not included in the initial testing [10]
| Marker | Upper Normal | Key Points |
|---|---|---|
| CA 19-9 | 37 U/mL | Often elevated in GBC but lacks sensitivity and specificity [1]. Also elevated in pancreatic cancer (72–79%), biliary cancer (67–73%), gastric cancer, CRC, and in benign biliary/pancreatic diseases (cholangitis, cholelithiasis, pancreatitis) [12]. Serial assay after resection may aid in diagnosis of persistent or recurrent disease [1]. Requires Lewis blood group antigen to be expressed — ~5–10% of the population are Lewis-negative and will never produce CA 19-9 regardless of disease |
| CEA | 5 ng/mL | May be elevated but neither sensitive nor specific. Primarily a CRC marker. Also elevated in smoking, liver disease, bowel diseases [12] |
| AFP | 10 ng/mL | Useful to differentiate from HCC (AFP elevated in HCC 70–90%; typically normal in GBC). Also elevated in hepatitis, cirrhosis [12][11] |
Tumour Markers — The Exam Trap
Common tumour markers such as AFP, CA19-9 and CEA are neither sensitive nor specific for periampullary tumours [10]. Absence of an elevated tumour marker does NOT exclude underlying malignancy [10]. Students frequently over-rely on tumour markers — they are supportive, not diagnostic. Their main utility is in serial monitoring after treatment to detect recurrence. [1]
| Test | Rationale |
|---|---|
| RFT (Renal function) | Baseline before contrast imaging (CT); assess hydration; hepatorenal syndrome |
| HBV and HCV serology | Differentiate from HCC (which is associated with viral hepatitis) [10] |
| Blood group and crossmatch | Preoperative if surgery planned |
| Glucose | Assess for DM (risk factor; also new-onset DM in elderly → consider pancreatic cancer) |
C. Radiological Investigations
USG is the initial imaging modality for any patient presenting with RUQ pain, jaundice, or suspected biliary pathology. It is cheap, non-invasive, widely available, and provides critical information.
Why USG first? Because it can quickly answer three key questions [12]:
- What is the size of the bile duct — is there any dilatation? (Normal intrahepatic ducts are < 2–3 mm and typically not visible on USG; CBD > 0.8 cm is pathological) [10]
- What is the level of obstruction?
- What is the cause of obstruction — stone or mass?
USG findings suggestive of GBC [1]:
| Finding | Interpretation |
|---|---|
| Thickened, irregular gallbladder wall > 3 mm | Focal or diffuse wall thickening — the most common USG finding in GBC; however, also seen in cholecystitis |
| Mass protruding into the gallbladder lumen or a fixed mass | Polypoid intraluminal mass or a mass replacing the GB — distinguishing feature: does NOT move with gravity (unlike a stone) and has NO acoustic shadow [2] |
| Loss of interface between gallbladder and liver | Direct tumour invasion into the liver bed (segments IVb/V) — the normal bright echogenic line between GB and liver is lost |
| Dilated biliary tree | Tumour obstructing CHD/CBD → upstream dilatation |
| Direct tumour infiltration into the liver | Hypoechoic mass extending from GB into liver parenchyma |
| Lymphadenopathy | Enlarged nodes at porta hepatis |
| Gallstones | Present in ~95% of GBC patients; may obscure the underlying mass |
USG Limitations
USG may be compromised by: excessive body fat, intraluminal bowel gas (especially obscuring the distal CBD), and the presence of gallstones which can shadow and obscure a small underlying mass. If USG is equivocal or shows concerning features, proceed to CT.
- More accurate for imaging the gallbladder than transabdominal USG [1] because the transducer is placed in the duodenum, directly adjacent to the gallbladder and bile ducts — eliminates the problem of bowel gas and body habitus
- Roles in GBC:
- Detailed assessment of GB wall layers → accurate T-staging
- Evaluation of regional lymph nodes (porta hepatis, peripancreatic)
- EUS-guided FNA/biopsy — for tissue diagnosis when percutaneous biopsy is risky or when the lesion is not accessible percutaneously [10]
- Limitations: Operator-dependent; limited availability; cannot assess distant metastases
CT with IV contrast is the workhorse for staging GBC. It answers the critical question: is this tumour resectable?
Key imaging protocol: Contrast-enhanced CT with arterial phase images to determine the anatomic course of the hepatic artery relative to the tumour, which is necessary to determine resectability [1]
CT findings consistent with GBC [1]:
| Finding | Significance |
|---|---|
| Focal or diffuse thickening of gallbladder wall | Most common pattern; may be indistinguishable from cholecystitis on a single scan |
| Polypoid mass protruding into the lumen or completely filling it | Intraluminal tumour growth; enhances with contrast |
| Direct liver infiltration | Tumour extending into liver segments IVb/V — determines need for liver resection |
| Nodal involvement | Enlarged nodes at porta hepatis, pericholedochal, peripancreatic, celiac, para-aortic — para-aortic nodes = distant disease → incurable |
| Presence of distant metastasis | Lung (CT thorax), peritoneal implants, liver metastases |
| Vascular involvement | Encasement or occlusion of hepatic artery or portal vein → T4 → generally unresectable |
| Invasion of adjacent organs | Stomach, duodenum, colon, pancreas involvement |
CT thorax is essential to detect distant metastases to the lung and pleura [1]
| Role | Details |
|---|---|
| Differentiate benign from malignant GB lesions in equivocal cases | MRI has superior soft tissue contrast compared to CT; T2-weighted MRCP images can differentiate between a neoplastic and inflammatory mass (e.g., xanthogranulomatous cholecystitis vs GBC) which may not be possible on USG or CT [1][13] |
| Visualisation of hepatoduodenal ligament invasion | Better assessment of the relationship between tumour and the portal vein, hepatic artery |
| Portal vein encasement and LN involvement | MRI with gadolinium enhancement can delineate vascular involvement |
| MRCP — biliary tree delineation | Non-invasive mapping of biliary anatomy; shows level and extent of biliary involvement; non-contrast, T2-weighted [14] |
MRCP vs ERCP
MRCP is non-invasive and has largely replaced ERCP as a diagnostic tool [10][14]. MRCP provides excellent biliary tree visualisation without the risks of ERCP (pancreatitis, bleeding, perforation). However, MRCP is NOT therapeutic — if you need to place a stent or take a biopsy, you need ERCP. So: MRCP for diagnosis, ERCP for intervention.
| Role | Details |
|---|---|
| Delineate the extent of biliary tree involvement | Cholangiogram shows strictures, filling defects, or complete obstruction |
| Helpful in coexisting jaundice | Indicates tumour growth into intrahepatic biliary ducts or CBD |
| Therapeutic | Place endoprosthesis (biliary stent) for palliative jaundice relief; sphincterotomy for stone removal |
| Brush cytology | Can obtain cytology from biliary stricture during ERCP (low sensitivity ~30–60%) |
ERCP indications in GBC:
- Preoperative biliary drainage when jaundice is severe and surgery needs to be delayed
- Palliative stenting for inoperable disease
- Differentiation from benign stricture (with brush cytology)
- Preferred over ERCP for obstruction at or above the level of confluence of hepatic ducts (i.e., hilar obstruction — because ERCP cannot reliably opacify ducts above a complete hilar obstruction) [14]
- Provides cholangiogram from above the obstruction
- Can place percutaneous transhepatic biliary drainage (PTBD) catheter for decompression
- Complications: bacteraemia (requires antibiotic prophylaxis), haemobilia [14]
| Aspect | Details |
|---|---|
| Utility | Clinical utility of PET scan in GBC is unclear and data are insufficient to make conclusive recommendations [1] |
| Main utility | Identifying otherwise radiographically occult advanced disease to avoid unnecessary surgery [1] — e.g., small peritoneal implants or distant LN metastases missed on CT |
| Limitations | High false-positive rate in inflammatory conditions (chronic cholecystitis causes FDG uptake); limited spatial resolution for small lesions |
Listed in staging investigations: PET/CT, laparoscopy [2]
This is one of the most important and commonly overlooked investigations in GBC workup.
Why is it needed?
- GBC frequently involves regional LNs or extends directly to adjacent structures which may preclude curative resection but may NOT be detectable by preoperative imaging such as CT or MRI scan [1]
- Mainly to confirm the absence of liver or peritoneal metastatic disease [1]
- Diagnostic staging laparoscopy identifies metastatic disease or other findings that contraindicate tumour resection [1]
What the surgeon looks for during staging laparoscopy:
- Peritoneal nodules (send for frozen section if suspicious)
- Liver surface metastases (not seen on CT if small/superficial)
- Omental disease
- Suspicious lymph nodes
When to perform: Before committing to a formal laparotomy for radical resection, particularly for T2 or higher disease
No promise of resection until laparotomy findings document absence of spread [10]
| Method | When to Use | Caveats |
|---|---|---|
| Intraoperative frozen section of cystic duct margin | During cholecystectomy — critical for determining the extent of additional resection needed [1][2] | Positive margin → bile duct resection + Roux-en-Y; Negative → LN dissection only |
| Percutaneous biopsy | Only for unresectable cases where histological confirmation is needed before chemotherapy [2][11] | Risk of tumour seeding along needle tract; risk of peritoneal dissemination |
| EUS-guided FNA | Alternative to percutaneous biopsy for lesions accessible via endoscopic approach | Lower theoretical risk of peritoneal seeding than percutaneous route |
| Histopathology of cholecystectomy specimen | The definitive diagnosis — most GBC is diagnosed on final pathology after cholecystectomy for presumed benign disease | Must examine the entire specimen thoroughly; identify T-stage to determine need for re-resection |
FNAC/Biopsy — ONLY for Unresectable Cases
FNAC or Trucut biopsy should ONLY be performed for unresectable cases [11]. For a potentially resectable tumour, biopsy is NOT performed preoperatively because:
- Tumour seeding — needle tract implantation of tumour cells
- Bile/tumour spillage → peritoneal dissemination
- The diagnosis can be confirmed on the surgical specimen itself
This principle applies broadly to hepatobiliary malignancies (HCC, cholangiocarcinoma, GBC). [11]
| Investigation | Primary Role | Key Findings in GBC | When to Use |
|---|---|---|---|
| Physical exam | Assess operability | Jaundice, hepatomegaly, ascites, Virchow's node, Sister Mary Joseph nodule | Always — first step |
| CBC | Baseline; sepsis screen | Leukocytosis, anaemia, thrombocytopenia | Always |
| Clotting | Pre-procedural | ↑ PT/INR (Vitamin K deficiency) | Always; correct before invasive Ix |
| LFT | Confirm cholestasis | ↑ ALP, ↑ GGT, ↑ conjugated bilirubin (cholestatic pattern) | Always |
| Tumour markers | Supportive; serial monitoring | CA 19-9, CEA elevated but NOT diagnostic | Always; interpret with caution |
| USG abdomen | 1st-line imaging | Wall thickening, mass, loss of GB-liver interface, dilated ducts, LN | Always — initial imaging |
| EUS | Detailed local assessment; biopsy | Wall layer invasion, LN, EUS-guided FNA | Equivocal USG; tissue diagnosis needed |
| CT T+A with contrast | Staging; resectability | Mass, liver invasion, LN, vascular involvement, distant mets | Always for suspected GBC |
| MRI/MRCP | Equivocal CT; biliary mapping | Differentiate benign vs malignant; biliary tree anatomy | Equivocal cases; preoperative planning |
| ERCP | Therapeutic; diagnostic | Biliary stricture, stenting, brush cytology | Jaundice requiring drainage |
| PTC | Proximal/hilar obstruction | Cholangiogram above obstruction; PTBD | Hilar obstruction not accessible by ERCP |
| PET/CT | Occult advanced disease | FDG-avid metastases missed on CT | Before planned radical surgery |
| Staging laparoscopy | Confirm resectability | Peritoneal/liver surface mets NOT seen on CT | Before laparotomy for T2+ disease |
| Intra-op frozen section | Cystic duct margin status | Positive → bile duct resection; Negative → LN dissection only | During surgery |
| Percutaneous biopsy | Tissue diagnosis | Adenocarcinoma on histology | ONLY for unresectable cases |
The ultimate goal of the diagnostic workup is to determine: can this tumour be resected with curative intent?
Absolute contraindications for radical resection [1]:
| Contraindication | Why It Makes Resection Futile |
|---|---|
| Liver metastasis | Distant haematogenous spread — systemic disease |
| Peritoneal metastasis | Transcelomic spread — systemic disease |
| Malignant ascites | Indicates peritoneal carcinomatosis |
| Encasement or occlusion of major vessels (hepatic artery / portal vein) | T4 disease; incomplete resection inevitable |
| Involvement of para-aortic, pericaval, SMA or celiac artery lymph nodes | Such involvement is considered distant rather than locoregional metastatic disease and therefore incurable [1] |
| Extensive involvement of the hepatoduodenal ligament | Direct tumour or nodal involvement makes R0 resection impossible |
This framework — assessment of patient status (good/bad) + assessment of tumour status (confined/spread) — is directly from the lecture slides [10]:
- Patient status good + Tumour confined → Laparotomy (radical resection)
- Patient status bad OR Tumour spread → PTBD or endoprosthesis (palliation)
High Yield Summary — Diagnosis of GBC
No formal diagnostic criteria — diagnosis is histopathological. Most GBC is diagnosed incidentally on cholecystectomy specimens.
Physical exam: Look for jaundice, hepatomegaly, Courvoisier's sign (usually absent in GBC), signs of inoperability (Virchow's node, ascites, Sister Mary Joseph nodule, Blumer's shelf).
Bloods: Cholestatic LFT pattern (↑↑ ALP, ↑ GGT, ↑ conjugated bilirubin). Tumour markers (CA 19-9, CEA) are NOT sensitive or specific — use for serial monitoring, not diagnosis. Clotting — check and correct Vitamin K deficiency before invasive procedures.
Imaging sequence: USG (1st line) → CT T+A with contrast (staging) → MRI/MRCP (equivocal) → PET/CT (occult advanced disease) → Staging laparoscopy (before committing to laparotomy).
Biopsy: ONLY for unresectable cases. For resectable tumours, intra-op frozen section of the cystic duct margin guides the extent of surgery.
Resectability: Unresectable if liver mets, peritoneal mets, malignant ascites, major vessel encasement, para-aortic/celiac/SMA LN involvement, or extensive hepatoduodenal ligament involvement.
Active Recall - Diagnosis of Gallbladder Cancer
[1] Senior notes: felixlai.md (Gallbladder cancer — Diagnosis and Treatment sections, pages 568–571) [2] Senior notes: maxim.md (Section 5.7 — Gallbladder carcinoma investigation and treatment) [10] Senior notes: felixlai.md (Malignant biliary obstruction — Diagnosis section, pages 501–503) [11] Lecture slides: WCS 064 - A large liver - by Prof R Poon [20191108].doc.pdf (p2) [12] Lecture slides: Malignant biliary obstruction.pdf (p7–8, p10) [13] Senior notes: felixlai.md (Mirizzi syndrome — Diagnosis section, page 574) [14] Senior notes: maxim.md (HBP investigations — MRCP and PTC sections)
Management of Gallbladder Cancer
The management of GBC is dictated by two fundamental assessments that must be made before any treatment decision [10][15][16]:
This framework — directly from the lecture slides — is the backbone of all hepatobiliary surgical oncology decision-making:
Why surgery? [16]
- Removal of tumour (oncological clearance)
- Relief of obstruction
- Pain control
The role of surgery in MBO has three goals [17]:
- R0 resection (absence of microscopic residual tumour — the gold standard)
- Relieve obstruction (jaundice, duodenal obstruction)
- Pain control (celiac plexus block)
The Lecture Slide Flowchart — Memorise This
From Prof R Poon's lecture [15]:
- General status BAD → PTBD or endoprosthesis
- General status GOOD + Tumour SPREAD → PTBD or endoprosthesis
- General status GOOD + Tumour CONFINED → Laparotomy
- At laparotomy: bypass if spread; radical resection if confined
This simple 2×2 framework applies to ALL malignant biliary obstruction, not just GBC. [15]
Preoperative Assessment
| Domain | Investigation | Rationale |
|---|---|---|
| Age / Comorbidities | Clinical history | Elderly or frail patients may not tolerate major hepatobiliary surgery |
| Hidden medical illness | CXR, ECG, Spirometry | Detect occult cardiopulmonary disease that increases perioperative mortality |
| Nutrition | LFT (albumin) | Malnutrition → poor wound healing, anastomotic leak, immunosuppression; cancer cachexia common |
| Fluid and electrolytes | RFT | Dehydration, renal impairment from obstructive uropathy or hepatorenal syndrome |
| Coagulopathy | CBC, Clotting profile | Vitamin K deficiency from obstructive jaundice → correct with IV Vitamin K (not oral — bile salts needed for oral absorption) + FFP if urgent surgery |
Clinical assessment — Signs of inoperability [10]:
- Irregular surface hepatomegaly (liver metastases)
- Troisier's sign (Virchow's node) — left supraclavicular LN
- Blumer's shelf — peritoneal metastasis palpable on DRE
- Sister Mary Joseph nodules — periumbilical metastasis
- Ascites — peritoneal carcinomatosis
Radiological assessment — Signs of inoperability [10]:
- LN metastasis (para-aortic, celiac, SMA nodes)
- Distant metastasis (liver, lung, peritoneum)
- Arterial involvement (SMA / celiac axis)
- Venous involvement (SMV / PV)
Criteria of resectability [18]:
- No distant metastases
- SMA and celiac axis not involved
- Patent superior mesenteric-portal venous confluence
- PV involvement is NOT an absolute contraindication — venous resection is appropriate to improve resectability and achieve R0 resection [10][18]
- However: significant morbidity and mortality; reasonable survival: median = 13 months, 5-year = 7% [18]
Preoperative Optimisation
| Aspect | Details |
|---|---|
| Goal | Target serum bilirubin < 50 µmol/L before surgery [19] |
| Methods | ERCP with endoprosthesis (stenting) or PTBD |
| Theoretically | Do NOT need to drain if no sepsis + early surgery can be offered within 1–2 weeks — preoperative biliary drainage increases risk of serious complications even in expert hands [19] |
| Practically (QMH) | Drain ALL patients since QMH cannot offer early surgery — Whipple/radical operations require 6–8 weeks waiting, and the chance of biliary sepsis is very high without drainage during this period [19] |
| Advantages | Minimise cholangitis risk; relieve jaundice/pruritus; prevent cholestasis complications; allow time for neoadjuvant therapy |
| Disadvantages | More interventions/costs; risk of procedure-related complications (cholangitis, pancreatitis, bleeding, perforation, stent blockage) |
Surgical Treatment — Curative Intent
Surgical treatment is the ONLY potentially curative treatment for GBC.
The specific operation depends entirely on the T-stage, which is determined either:
- Preoperatively on imaging, OR
- Intraoperatively on frozen section (for incidentally discovered GBC)
| T Stage | Surgical Approach | Rationale |
|---|---|---|
| Tis | Simple cholecystectomy | Carcinoma in situ — no invasion beyond epithelium; zero risk of nodal/distant spread |
| T1a | Simple cholecystectomy | Invasion limited to lamina propria only; lymphatics are in the subserosa, so T1a has minimal risk of nodal disease (< 2.5%) [1] |
| T1b | Extended cholecystectomy + LN dissection | Invasion into muscular layer; nodal metastasis risk rises to ~10–15% — enough to justify lymphadenectomy |
| T2 | Extended cholecystectomy + LN dissection | Invasion through muscularis into perimuscular connective tissue; nodal metastasis risk ~20–30%; T2b (hepatic side) may have direct liver invasion [1][2] |
| T3 | Extended cholecystectomy + en-bloc removal of involved adjacent organ + LN dissection | Tumour perforates serosa or invades liver/one adjacent organ; more aggressive resection needed to clear margins |
| T4 | Generally locally unresectable | Invasion of main portal vein or hepatic artery or ≥ 2 extrahepatic organs → cannot achieve R0 [1] |
"In general... Radical cholecystectomy for CA gallbladder" [17]
| Feature | Open | Laparoscopic |
|---|---|---|
| Recommendation | Open approach is generally recommended for GBC [1] | Not recommended for known/suspected GBC |
| Why open? | Port site recurrences and late peritoneal metastasis associated with bile spillage are reported with laparoscopic approach [1] | Laparoscopic manipulation risks tumour rupture and peritoneal contamination |
| Incision | Right subcostal incision (Kocher incision) [1] | N/A |
| Extended exposure | Extension to upper midline or left subcostal region as a chevron incision [1] | N/A |
Indications for open cholecystectomy (rather than laparoscopic) [3]:
- CA gallbladder (extensive adhesions, risk of rupture and tumour seeding)
- Cannot tolerate pneumoperitoneum (cardiopulmonary comorbidities)
- Refractory coagulopathy
- Multiple abdominal surgeries
Why NOT Laparoscopic for GBC?
The laparoscopic approach is contraindicated for known or suspected GBC because:
- Port-site metastasis — tumour cells seed along trocar tracks (reported in up to 10–20% of cases)
- Bile spillage — pneumoperitoneum + gallbladder manipulation → GB perforation → bile containing tumour cells spills into peritoneal cavity → peritoneal carcinomatosis
- Inadequate resection — difficult to perform en-bloc liver resection + formal lymphadenectomy laparoscopically
If GBC is found incidentally DURING a laparoscopic cholecystectomy, convert to open if feasible, or stop and plan re-resection as a staged open procedure. [1][3]
Indication: Tis and T1a tumours
- Very early stage tumours including Tis and T1a can be cured with simple cholecystectomy alone [1]
- Why is this sufficient?
- T1a invades only the lamina propria. Lymphatics reside in the subserosal layer — the tumour has not yet reached the lymphatic highway. Therefore, the risk of nodal metastasis is < 2.5%
- Cystic duct margin is checked — if positive, further resection is needed
- Stage I disease (confined to mucosa, T1N0): no further treatment required [2]
- 5-year survival for T1a: ~85–100%
Indication: T1b and higher (when resectable)
The concept: "Open cholecystectomy with intra-op frozen section" [2] → if T1b or higher on histology, extend the operation.
Extended cholecystectomy involves [1][2]:
-
En-bloc removal of gallbladder + rim of liver
- Rim of liver at ≥ 2 cm adjacent to the gallbladder bed OR a formal central liver resection (Segment IVb and V) [1]
- Why? The gallbladder body is directly adherent to liver segments IVb and V via loose connective tissue with no serosa — tumour invades directly into these segments. You must resect the liver beneath the gallbladder bed to ensure clear margins
- Patients with tumours of the fundus or body: tumour is generally far enough from the inflow structures to allow a negative-margin resection with ≥ 2 cm non-anatomical wedge resection or anatomic resection of segment IVb and V [1]
- More aggressive surgery may be necessary including resection of additional liver segments if there is evidence of tumour infiltration beyond segments IVb/V [1]
-
Regional lymphadenectomy [1][2]
- Porta hepatis LN [2]
- Proper LN dissection involves removing ALL LNs in the porta hepatis and along the hepatoduodenal ligament (cystic duct, CBD, hepatic artery, portal vein), paraduodenal, peripancreatic, and celiac LNs [1]
- At least 6 lymph nodes should be removed for proper staging [1]
- Why 6? This is the minimum needed to accurately stage N disease. Inadequate lymph node harvest leads to understaging and potentially undertreating
-
± Extrahepatic bile duct resection [1][2]
- Only performed when gross tumour extends into CBD or when a negative cystic duct margin cannot be obtained by intraoperative frozen section [1]
- If cystic duct margin positive → Regional LN dissection + Extrahepatic bile duct resection with reconstruction by Roux-en-Y hepaticojejunostomy [1]
- If cystic duct margin negative → Regional LN dissection only [1]
Routine Bile Duct Resection — NOT Recommended
Routine bile duct resection with an attempt to achieve a more complete lymphadenectomy is NOT associated with survival benefit and has potential serious complications such as bile leak and anastomotic stricture with hepaticojejunostomy reconstruction [1]. Only resect the bile duct when there is a clear indication (positive cystic duct margin or gross tumour in the CBD).
Intraoperative frozen section of the cystic duct is performed during every cholecystectomy for GBC (or when GBC is suspected):
| Cystic Duct Margin | Action |
|---|---|
| Negative | Regional LN dissection only [1] |
| Positive | Regional LN dissection + Extrahepatic bile duct resection + Roux-en-Y hepaticojejunostomy [1] |
Why? A positive cystic duct margin means tumour extends into the CBD — leaving this behind guarantees local recurrence and makes the surgery non-curative.
Roux-en-Y hepaticojejunostomy ("Roux" = named after surgeon César Roux; "en-Y" = the shape of the bowel loop; "hepatico-" = hepatic duct; "jejunostomy" = anastomosis to jejunum):
- A loop of jejunum is divided
- The distal limb is brought up and anastomosed to the residual hepatic duct(s) — this restores bile drainage from the liver into the gut
- The proximal limb is anastomosed to the side of the Roux limb downstream — creating the "Y" shape
- This is the standard reconstruction after bile duct resection
This is one of the most commonly tested scenarios in exams.
Scenario: Patient undergoes elective laparoscopic cholecystectomy for gallstones. Final histopathology unexpectedly shows adenocarcinoma.
| T Stage on Final Path | Management |
|---|---|
| Tis / T1a | No further surgery needed — cholecystectomy alone is curative |
| T1b or higher | Re-resection required: Open radical (extended) cholecystectomy with completion liver resection (segment IVb/V wedge or formal resection) + LN dissection ± bile duct resection. Also: excise all port sites (risk of tumour seeding) |
Why excise port sites? During laparoscopic cholecystectomy, the gallbladder is extracted through a port (usually umbilical). If there was bile spillage or direct contact of the tumour with the port site, tumour cells may have implanted there. Excision of all port sites is standard practice for incidental GBC.
| Contraindication | Rationale |
|---|---|
| Liver metastasis | Haematogenous distant spread — systemic disease |
| Peritoneal metastasis | Transcelomic distant spread |
| Malignant ascites | Indicates peritoneal carcinomatosis |
| Encasement or occlusion of major vessels (hepatic artery / portal vein) | T4 disease — cannot achieve R0 |
| Involvement of para-aortic, pericaval, SMA or celiac artery lymph nodes | Such involvement is considered distant rather than locoregional metastatic disease and therefore incurable [1] |
| Extensive involvement of the hepatoduodenal ligament | Direct tumour or nodal involvement makes R0 impossible |
Non-Surgical / Palliative Treatment
The majority of patients with GBC have unresectable disease at the time of diagnosis [1]. For these patients, the goals shift from cure to symptom palliation and quality of life.
Three main indications for palliation [10][20]:
- Biliary obstruction → relieve jaundice
- Duodenal obstruction → relieve gastric outlet obstruction
- Pain → control cancer-related pain
1. Relief of Obstructive Jaundice
ERCP with endoprosthesis is ALWAYS 1st line regardless of the level of obstruction [10], except:
- Contraindications for ERCP (structural upper GI abnormalities, post-Billroth II or Roux-en-Y anatomy)
- Multiple stenting required or difficulty reaching intrahepatic bile ducts (e.g., hilar obstruction → may need PTC)
| Aspect | Details |
|---|---|
| Mechanism | Stent placed across the malignant stricture holds the bile duct open → bile drains from liver into duodenum → jaundice resolves |
| Types of stents | Metallic stent is preferred if confirmed inoperable — more durable than plastic stent (patency: metal ~6–12 months vs plastic ~3 months) [10] |
| Self-expanding metallic stents (SEMS) | For established malignancy (longer patency, but cannot be removed) [21] |
| Uncovered stents preferred | Lower risk of occluding branches of the biliary system [21] |
| Complications | Stent occlusion (sludge / tumour ingrowth / tumour overgrowth) [10][21], stent migration [21], cholangitis, cholecystitis |
| Management of occlusion | Sweeping or placing a new stent [21] |
ERCP is preferred over PTBD because [10]:
- PTBD is technically more difficult
- Bleeding is common due to puncture of hepatic artery or portal vein before reaching the bile duct (portal triad) [10]
| Type | Indication | Notes |
|---|---|---|
| Simple external PTBD | Short-term drainage to bridge to surgery | Catheter drains bile externally; prone to electrolyte and fluid loss due to bile output [10] |
| External-internal PTBD | Long-term palliation | Catheter is pushed past the obstruction into the duodenum → bile drains internally; if tube is clamped, drainage is completely internal [10] |
Approaches to biliary drainage [21]:
- Internal drainage: ERCP + stenting
- External drainage: PTBD
- Internal-external drainage: PTBD pushed past obstruction → internalised
If PTBD catheter causes bleeding [10]:
- Stabilise and resuscitate
- Clamp the PTBD catheter
- Perform cholangiogram by injecting contrast into PTBD to determine whether catheter is in hepatic artery or portal vein
- Remove catheter slowly to control bleeding — do NOT attempt to remove immediately as it will convert into free haemoperitoneum
- Reserved for patients who undergo laparotomy but are found to have unresectable disease
- Bypass if spread [15]
- Biliary bypass: Hepaticojejunostomy or choledochojejunostomy (NOT choledochoduodenostomy — duodenum is too close to tumour) [20]
- Advantage: long-term relief without risk of stent occlusion; but requires laparotomy
GBC can directly invade the duodenum (body of GB abuts D1/D2) causing gastric outlet obstruction.
| Option | Details |
|---|---|
| Endoscopic duodenal stenting | Self-expanding metallic stent placed across the duodenal stricture — less invasive than surgery |
| Gastrojejunostomy | Surgical bypass connecting stomach to jejunum, bypassing the obstructed duodenum (a "double bypass" if combined with biliary bypass) |
| Surgical bypass for duodenal obstruction [2] | Indicated when endoscopic stenting fails or is not feasible |
Double bypass (biliary + gastric bypass) — performed when inoperable disease is found at laparotomy [20]:
- Biliary bypass: choledochojejunostomy (relieves jaundice)
- Gastric bypass: gastrojejunostomy (relieves GOO)
- Also: obtain transduodenal trucut biopsy ± celiac plexus block [20]
| Modality | Details |
|---|---|
| Analgesics (WHO pain ladder) | Paracetamol → weak opioids (tramadol, codeine) → strong opioids (morphine, fentanyl) |
| Celiac plexus block (neurolysis) | Endoscopic USG / CT-guided celiac plexus neurolysis [10][20] — injection of alcohol or phenol around the celiac plexus (T12/L1 level) destroys the sympathetic afferent fibres carrying visceral pain from the gallbladder and upper abdomen. Provides durable pain relief in ~70–80% of patients |
| Short-course radiotherapy | Can provide local pain relief for bulky, symptomatic tumour |
Adjuvant and Systemic Therapy
- Indication: All patients with T2 or higher GBC who undergo R0/R1 resection (especially node-positive disease)
- The BILCAP trial (2019) established capecitabine as the standard adjuvant chemotherapy for resected biliary tract cancers (including GBC), showing improved overall survival [1]
- Other options:
- Gemcitabine + cisplatin (extrapolated from ABC-02 trial for advanced biliary cancers)
- Gemcitabine + capecitabine
- Adjuvant chemotherapy should be started within 8–12 weeks of surgery
- For unresectable, locally advanced, or metastatic GBC
- First-line: Gemcitabine + cisplatin (ABC-02 trial) — the standard of care for advanced biliary tract cancers
- Alternatives: FOLFOX, capecitabine, 5-FU/leucovorin
- Newer options (biomarker-driven):
- Pembrolizumab/Durvalumab (immune checkpoint inhibitors) — for MSI-high or PD-L1 positive tumours (TOPAZ-1 trial: durvalumab + gemcitabine/cisplatin improved OS)
- HER2-targeted therapy (trastuzumab deruxtecan) — for ERBB2-amplified tumours
- IDH1 inhibitors (ivosidenib) — for IDH1-mutated tumours (more relevant to cholangiocarcinoma)
- FGFR inhibitors (pemigatinib, futibatinib) — for FGFR2 fusion/rearrangement (more relevant to intrahepatic cholangiocarcinoma)
- Role is controversial and not established as standard
- May be considered for positive margins (R1 resection) or locally advanced disease
- Often combined with chemotherapy as chemoradiation
Majority of patients with gallbladder cancer have unresectable disease at the time of diagnosis [1] 5-year survival for all patients with gallbladder cancer is < 5% with a median survival of 6 months [1]
| Stage | 5-Year Survival | Key Factor |
|---|---|---|
| Tis / T1a | 85–100% | Simple cholecystectomy curative |
| T1b | 50–70% | Extended cholecystectomy + LND |
| T2 | 20–40% | Extended cholecystectomy + LND |
| T3 | 5–15% | Aggressive multimodal therapy |
| T4 / M1 | < 5% | Palliative only |
High Yield Summary — Management of GBC
Framework: Assess patient status (good/bad) + tumour status (confined/spread) [15]
- Good + Confined → Laparotomy → Radical resection if confirmed confined
- Bad OR Spread → PTBD or endoprosthesis (Palliation)
Treat SEPSIS first [16]. Preoperative biliary drainage to bilirubin < 50 µmol/L [19].
Surgery by T-stage:
- Tis / T1a → Simple cholecystectomy (curative)
- T1b / T2 → Extended cholecystectomy (GB + liver wedge ≥ 2cm or Seg IVb/V + LN dissection)
- T3 → Extended cholecystectomy + en-bloc adjacent organ resection
- T4 → Generally unresectable
Open approach recommended (port-site recurrence risk with laparoscopic) [1][3]
Intra-op frozen section of cystic duct: Positive → bile duct resection + Roux-en-Y; Negative → LN dissection only [1]
Routine bile duct resection NOT recommended (no survival benefit, serious complications) [1]
At least 6 LNs must be harvested for proper staging [1]
Palliation: ERCP stenting (1st line) > PTBD > surgical bypass. Metallic stent preferred if confirmed inoperable [10]. Celiac plexus block for pain. Gastrojejunostomy for duodenal obstruction.
Adjuvant chemo: Capecitabine (BILCAP) for resected T2+. Palliative chemo: Gemcitabine + cisplatin ± durvalumab.
Prognosis: 5-year OS < 5% overall; median survival 6 months [1]
Active Recall - Management of Gallbladder Cancer
References
[1] Senior notes: felixlai.md (Gallbladder cancer — Treatment and Prognosis sections, pages 569–571) [2] Senior notes: maxim.md (Section 5.7 — Gallbladder carcinoma treatment) [3] Senior notes: maxim.md (Cholecystectomy — Indications and approach) [7] Senior notes: felixlai.md (Gallbladder cancer — Treatment by stage, page 569) [10] Senior notes: felixlai.md (Malignant biliary obstruction — Treatment section, pages 503–505) [15] Lecture slides: WCS 056 - Painless jaundice and epigastric mass - by Prof R Poon.ppt (1).pdf (p48, p54) [16] Lecture slides: Malignant biliary obstruction.pdf (p18) [17] Lecture slides: Malignant biliary obstruction.pdf (p19, p21) [18] Lecture slides: Malignant biliary obstruction.pdf (p23) [19] Senior notes: felixlai.md (Malignant biliary obstruction — Preoperative biliary drainage and surgical treatment, pages 505–507) [20] Senior notes: felixlai.md (Pancreatic cancer — Palliative treatment, page 598) [21] Senior notes: maxim.md (Cholangiocarcinoma — Palliative care, stenting)
Complications of Gallbladder Cancer
Complications of GBC can be organised into three major categories:
- Complications of the disease itself (from tumour growth and spread)
- Complications of surgical treatment (from cholecystectomy and extended resection)
- Complications of palliative interventions (from stenting, PTBD, and chemotherapy)
Understanding these from first principles means linking each complication back to the anatomy, the natural history of GBC, and the specific physiological insults of each treatment.
I. Complications of the Disease Itself
These arise from the local invasion, biliary obstruction, metastatic spread, and systemic effects of GBC.
GBC causes biliary obstruction by three mechanisms (cystic duct LN compression, direct CBD infiltration, tumour fragments) [8]. Once bile flow is obstructed, a cascade of complications follows:
| Complication | Pathophysiological Basis |
|---|---|
| Conjugated hyperbilirubinaemia / Jaundice | Bile cannot drain into duodenum → conjugated bilirubin refluxes into blood → deposits in skin, sclera (visible when bilirubin > 35 µmol/L) |
| Pruritus | Bile salts normally excreted in bile accumulate in blood → deposit in skin → stimulate cutaneous nerve endings. Severe, intractable pruritus significantly impairs quality of life |
| Dark urine / Pale stools | Conjugated bilirubin (water-soluble) excreted by kidneys → dark "tea-coloured" urine. No bilirubin reaching gut → no stercobilinogen → pale/clay stools |
| Coagulopathy | No bile salts in the gut → cannot emulsify dietary fat → impaired absorption of fat-soluble vitamins (A, D, E, K). Vitamin K deficiency → impaired hepatic synthesis of clotting factors II, VII, IX, X → prolonged PT/INR → bleeding tendency [1][10][22] |
| Malabsorption and malnutrition | Fat malabsorption → steatorrhoea (floating, foul-smelling, pale, greasy stools). Also: loss of fat-soluble vitamins → Vitamin A deficiency (night blindness), Vitamin D deficiency (osteomalacia/osteoporosis), Vitamin E deficiency (neuropathy) [22] |
| Immune dysfunction | Cholestasis impairs reticuloendothelial system function and cell-mediated immunity. The liver normally clears endotoxin from portal blood; in obstructive jaundice, this clearance is impaired → endotoxaemia → increased susceptibility to sepsis [10][22] |
| Renal failure | Conjugated bilirubin and bile salts are directly nephrotoxic. Also: endotoxaemia in cholestatic patients causes renal vasoconstriction → hepatorenal physiology. Studies from the 1980s showed higher rates of renal failure in jaundiced patients undergoing surgery [22] |
The lecture slide summarises these consequences neatly: "Jaundice → coagulopathy, malabsorption, malnutrition and immune dysfunction" [22]
- When bile stasis occurs proximal to a malignant obstruction, the stagnant bile becomes a fertile medium for bacterial growth
- Bacteria ascend from the duodenum or reach the bile via the portal circulation
- Common organisms: E. coli, Klebsiella, Enterococcus faecalis (same as for any cholangitis)
- Presents as Charcot's triad (fever + jaundice + RUQ pain) or Reynolds' pentad (adds hypotension + altered mental status)
- Biliary sepsis is one of the leading causes of mortality in MBO [23]
Causes of Mortality in MBO
The lecture slides explicitly list three causes of mortality [23]:
- Biliary sepsis — infection of obstructed, stagnant bile → bacteraemia → septic shock
- Cancer cachexia — tumour-derived cytokines (TNF-α, IL-6) → progressive wasting → organ failure
- Liver failure — chronic biliary obstruction → secondary biliary cirrhosis → hepatic decompensation; also direct tumour invasion destroying liver parenchyma
The anatomy of the gallbladder means that as tumour grows, it invades neighbouring structures in a predictable pattern [1]:
| Structure Invaded | Resulting Complication | Why (Anatomical Basis) |
|---|---|---|
| Liver (Segments IVb, V) | Hepatic insufficiency, portal hypertension, liver failure | GB body directly adherent to liver via loose connective tissue with no serosa on hepatic side; venous drainage flows directly into these segments |
| Duodenum (D1/D2) | Gastric outlet obstruction / duodenal obstruction → nausea, vomiting, inability to eat | GB body free margin abuts the duodenum inferiorly [1] |
| Hepatic flexure of colon | Large bowel obstruction (rare) | GB fundus is anatomically associated with the hepatic flexure [1] |
| Stomach | Gastric outlet obstruction; fistula formation (rare) | Proximity of GB body to gastric antrum |
| Pancreas | Secondary pancreatitis; exocrine/endocrine insufficiency | Head of pancreas adjacent to distal CBD and duodenum |
| Extrahepatic bile ducts | Obstructive jaundice (as discussed above) | Tumour at neck/cystic duct directly infiltrates CHD/CBD |
| Hepatoduodenal ligament | Portal vein or hepatic artery encasement → portal hypertension → ascites, variceal bleeding | The hepatoduodenal ligament contains the portal triad (portal vein, hepatic artery, CBD); tumour or nodes invading this ligament compromise all three structures |
| Omentum / Peritoneum | Peritoneal carcinomatosis → malignant ascites | Transcelomic spread from serosal penetration (T3+) |
| Abdominal wall | Tumour nodule in abdominal wall (rare) | Direct invasion through the peritoneum |
Sites of distant metastasis include lung, pleura, and peritoneum [1]
| Metastatic Site | Complications |
|---|---|
| Liver (haematogenous via cystic veins) | Progressive hepatic insufficiency; portal hypertension |
| Peritoneum | Malignant ascites (exudative); bowel obstruction from carcinomatosis |
| Lung and pleura | Malignant pleural effusion → dyspnoea; pulmonary nodules |
| Lymph nodes (para-aortic, celiac, SMA) | Compression of adjacent structures; considered distant metastasis and therefore incurable |
| Port-site metastasis | Recurrence at trocar sites after prior laparoscopic cholecystectomy — port site recurrences and late peritoneal metastasis associated with bile spillage are reported [1] |
| Complication | Mechanism |
|---|---|
| Cancer cachexia [23] | Tumour-derived pro-inflammatory cytokines (TNF-α/cachectin, IL-1, IL-6) → increased basal metabolic rate + skeletal muscle proteolysis + adipose tissue lipolysis + anorexia. Leads to progressive wasting, weakness, and ultimately multi-organ failure |
| Venous thromboembolism (VTE) | Mucin-producing adenocarcinomas (like GBC) activate the coagulation cascade → hypercoagulable state → DVT/PE. Also known as Trousseau syndrome (migratory superficial thrombophlebitis) |
| Anaemia of chronic disease | Chronic inflammation → hepcidin elevation → iron sequestration in macrophages → functional iron deficiency → normocytic normochromic anaemia |
II. Complications of Surgical Treatment
These are divided by the specific operation performed.
Even simple cholecystectomy carries risks. Since GBC requires an open approach, the complication profile differs slightly from elective laparoscopic cholecystectomy.
Immediate:
- Conversion to open surgery (if started laparoscopically — 5% elective, 25% emergency) — NOT an indication of failure [24]
- GA risks, haemorrhage
- Damage to neighbouring structures [24]:
- Bile duct injury → bile leakage (the most feared complication of any cholecystectomy)
- Cystic artery bleeding
- Duodenal, transverse colon, or hepatic flexure injury (especially during difficult dissection in inflamed Calot's triangle)
Early (days to weeks):
| Complication | Mechanism | Management |
|---|---|---|
| Biliary leakage (from cystic duct stump or duct of Luschka — 0.5%) [24] | Insecure clip on cystic duct stump; or injury to an accessory bile duct (duct of Luschka) draining directly from the liver bed into the gallbladder | Minor: ERCP + stent to reduce transsphincteric pressure gradient → promotes healing. Major: Laparotomy + lavage + Roux-en-Y hepaticojejunostomy [24] |
| Bleeding | Liver (middle hepatic vein close to GB fossa), cystic artery, trocar site | Haemostasis; may require re-exploration |
| Post-operative jaundice | Dropped/missed CBD stones; retained cystic duct stone; bile duct injury | ERCP for stone removal; surgical repair if duct injury |
| Cholangitis | Infected retained stone; biliary stasis | Antibiotics + ERCP drainage |
| Post-operative diarrhoea | Initial uncoordinated excessive bile salt excretion + fat malabsorption [24] — without the gallbladder to store and concentrate bile, a larger volume of dilute bile enters the colon continuously | Usually self-limiting; bile salt binders (cholestyramine) if persistent |
Late (weeks to months):
| Complication | Mechanism | Management |
|---|---|---|
| Bile duct stricture | Ischaemic injury to the bile duct wall during dissection → fibrosis → narrowing | Reconstruction ± hepaticojejunostomy [24] |
| Subphrenic abscess | Infected collection in the subphrenic space from bile/blood leak | Percutaneous drainage + antibiotics [24] |
| Post-cholecystectomy syndrome | Persistent symptoms (biliary colic, diarrhoea) after operation [24] — due to sphincter of Oddi dysfunction, retained CBD stones, bile duct stricture, or non-biliary causes (IBS, peptic ulcer) | Investigate with MRCP/ERCP; treat underlying cause |
| Post-cholecystectomy choledocholithiasis | Bile stasis due to increased CBD calibre (loss of GB storing function) [24] → new stone formation in CBD | ERCP stone extraction |
Extended cholecystectomy adds liver resection + lymphadenectomy ± bile duct resection, each contributing specific complications:
| Complication | Mechanism | Relevant to Which Component |
|---|---|---|
| Haemorrhage (intra/post-operative) | Liver parenchymal transection → bleeding from hepatic veins, portal vein branches, or raw liver surface | Liver resection |
| Bile leak | Cut surface of liver (especially gallbladder fossa) has small bile ductules that can leak; also from hepaticojejunostomy anastomosis | Liver resection; bile duct resection |
| Anastomotic stricture (of Roux-en-Y hepaticojejunostomy) | Fibrosis and scarring at the surgical anastomosis → narrowing → recurrent jaundice, cholangitis | Bile duct resection with reconstruction. Routine bile duct resection is NOT associated with survival benefit and has potential serious complications such as bile leak and anastomotic stricture [1] |
| Liver failure / Post-hepatectomy liver failure | Insufficient future liver remnant (FLR) after resection — the remaining liver cannot sustain synthetic, metabolic, and excretory functions | Liver resection (especially if underlying liver disease or extensive resection) |
| Subphrenic / Perihepatic abscess | Infected collection at the liver resection surface or in the subphrenic space | Liver resection |
| Lymphatic leak / Chylous ascites | Disruption of lymphatic channels during extensive porta hepatis lymphadenectomy | Lymph node dissection |
| Portal vein thrombosis | Endothelial injury during dissection around the portal vein; low flow states post-operatively | Lymph node dissection / vascular manipulation |
| Wound infection / Dehiscence | Large right subcostal or chevron incision in a malnourished, jaundiced, immunocompromised patient | Open approach; host factors |
Why Is MBO High Risk for Surgery?
The lecture slides identify three key reasons why MBO patients are high-risk surgical candidates [19]:
- Cancer cachexia → Malnutrition → Nutritional support needed
- Liver derangement → Bleeding tendency → IV Vitamin K and FFP during surgery
- Superimposed biliary infection → Antibiotic cover essential
These factors all converge to increase the risk of post-operative haemorrhage, infection, poor healing, and organ failure.
When GBC is discovered incidentally after laparoscopic cholecystectomy:
| Complication | Mechanism |
|---|---|
| Port-site recurrence | Tumour cells seed along trocar tracks during laparoscopic GB extraction — reported in 10–20% of incidental GBC cases. This is why port sites must be excised during re-resection [1] |
| Peritoneal carcinomatosis | Bile spillage during laparoscopic cholecystectomy → tumour-containing bile contaminates the peritoneal cavity → peritoneal metastasis [1] |
| Incomplete initial resection | Simple laparoscopic cholecystectomy is inadequate for T1b+ disease → residual disease in liver bed and lymph nodes → local and distant recurrence if re-resection is not performed |
III. Complications of Palliative Interventions
| Complication | Mechanism | Management |
|---|---|---|
| Stent occlusion | Sludge, tumour ingrowth (tumour grows through mesh of metallic stent), tumour overgrowth (tumour grows over the ends of stent) [10] | Sweeping (mechanical cleaning) or placing a new stent through the occluded one [21] |
| Stent migration | Stent shifts position → loss of drainage → recurrent jaundice | Endoscopic retrieval and replacement [21] |
| Cholangitis | Introduction of bacteria during ERCP; stent becomes a nidus for infection; incomplete drainage | IV antibiotics; stent exchange or drainage |
| Post-ERCP pancreatitis | Cannulation-related oedema of the pancreatic duct orifice → obstruction of pancreatic drainage → autodigestion | Conservative (NPO, IVF, analgesia); usually self-limiting |
| Bleeding | Sphincterotomy → arterial bleeding from papilla | Endoscopic haemostasis; correct coagulopathy first |
| Perforation | Retroduodenal perforation during sphincterotomy; guide wire perforation of bile duct | Surgical repair if large; conservative if contained |
| Cholecystitis (stent-related) | Metallic stent may cover the cystic duct orifice → bile cannot drain from gallbladder → acute cholecystitis. Uncovered stents are preferred to reduce this risk [21] | Percutaneous cholecystostomy or cholecystectomy if feasible |
Pre-op biliary drainage has increased risk of serious complications — pancreatitis (7%), cholangitis (26%), blocked stent (15%), bleeding (2%), perforation (2%) [22]
| Complication | Mechanism | Management |
|---|---|---|
| Bleeding | Common due to puncture of hepatic artery or portal vein before reaching the bile duct (portal triad) [10] | Stabilise and resuscitate → Clamp the PTBD catheter → Perform cholangiogram to determine if catheter is in hepatic artery or portal vein → Remove catheter slowly (do NOT remove immediately — converts to free haemoperitoneum) [10] |
| Bacteraemia / Sepsis | Introducing bacteria during the procedure; manipulation of an infected obstructed system | Prophylactic antibiotics before procedure |
| Haemobilia | Hepatic artery branch fistula to bile duct from catheter trauma | Angiographic embolisation |
| Electrolyte and fluid loss | Simple external PTBD is prone to electrolyte and fluid loss due to bile output [10] — bile contains Na+, K+, HCO3−, Cl−. Losing ~500–1000 mL bile daily causes dehydration and metabolic acidosis | IVF replacement; convert to internal-external drainage |
| Catheter dislodgement | Accidental pull-out | Re-insertion; consider internal stenting |
| Bile peritonitis | Bile leaks around catheter insertion site into peritoneal cavity | Catheter adjustment; percutaneous drain; laparotomy if severe |
| Agent | Key Toxicities | Mechanism |
|---|---|---|
| Gemcitabine | Myelosuppression (neutropaenia, thrombocytopaenia), nausea, hepatotoxicity, flu-like symptoms | Nucleoside analogue → inhibits DNA synthesis in rapidly dividing cells (bone marrow, GI mucosa) |
| Cisplatin | Nephrotoxicity, ototoxicity, peripheral neuropathy, severe nausea | Platinum cross-links DNA; accumulates in renal tubular cells |
| Capecitabine | Hand-foot syndrome (palmar-plantar erythrodysaesthesia), diarrhoea, mucositis | Oral prodrug of 5-FU; activated preferentially in tumour tissue but also affects skin and GI mucosa |
| Durvalumab (immune checkpoint inhibitor) | Immune-related adverse events: pneumonitis, colitis, hepatitis, thyroiditis, adrenalitis | PD-L1 blockade → unleashes T-cell activity → autoimmune inflammation in various organs |
Even after apparently curative R0 resection, GBC has a high recurrence rate:
| Pattern of Recurrence | Mechanism | Detection |
|---|---|---|
| Local recurrence (liver bed, porta hepatis) | Microscopic residual disease at resection margins; perineural invasion | CT/MRI; rising CA 19-9 |
| Peritoneal recurrence | Transcoelomic dissemination (especially if there was bile spillage at index operation) | CT; diagnostic laparoscopy |
| Distant recurrence (lung, bone) | Haematogenous spread via cystic veins → systemic circulation | CT thorax; bone scan; PET/CT |
| Port-site recurrence | Tumour seeding during prior laparoscopic surgery | Clinical examination; CT of abdominal wall |
Serial CA 19-9 monitoring after resection can aid in detection of persistent or recurrent disease — a rising trend is concerning even if imaging is negative [1]
| Category | Key Complications |
|---|---|
| Disease — Obstruction | Jaundice, cholangitis/biliary sepsis, coagulopathy, malabsorption, renal failure, immune dysfunction |
| Disease — Invasion | Liver failure, GOO/duodenal obstruction, peritoneal carcinomatosis, malignant ascites |
| Disease — Metastasis | Lung/pleural mets, peritoneal disease, port-site recurrence |
| Disease — Systemic | Cancer cachexia, VTE/Trousseau syndrome, anaemia of chronic disease |
| Surgery — General | Haemorrhage, wound infection, bile leak, bile duct injury, post-op jaundice |
| Surgery — Extended | Liver failure, anastomotic stricture, bile leak from raw surface, lymphatic leak, portal vein thrombosis |
| Palliation — ERCP | Stent occlusion, stent migration, cholangitis, pancreatitis, perforation, bleeding |
| Palliation — PTBD | Bleeding (hepatic artery/PV puncture), sepsis, electrolyte loss, catheter dislodgement |
| Chemotherapy | Myelosuppression, nephrotoxicity, hand-foot syndrome, immune-related adverse events |
| Causes of death | Biliary sepsis, cancer cachexia, liver failure [23] |
High Yield Summary — Complications of GBC
Disease complications: Obstructive jaundice → coagulopathy (Vit K malabsorption), malabsorption, immune dysfunction, renal failure. Biliary sepsis (cholangitis). Direct invasion → GOO (duodenum), liver failure, peritoneal carcinomatosis. Distant mets: lung, pleura, peritoneum [1].
Three causes of mortality in MBO: biliary sepsis, cancer cachexia, liver failure [23]
Surgical complications: Bile leak (cystic duct stump, duct of Luschka, liver cut surface, anastomosis). Routine bile duct resection risks bile leak and anastomotic stricture without survival benefit [1]. Post-hepatectomy liver failure. Port-site recurrence if prior laparoscopic approach.
Palliative intervention complications: Stent occlusion (sludge/ingrowth/overgrowth), stent migration [10][21]. PTBD bleeding from hepatic artery/PV puncture [10]. Pre-op drainage complications: pancreatitis 7%, cholangitis 26%, blocked stent 15% [22].
Post-cholecystectomy: Biliary leakage 0.5%, bile duct stricture, post-cholecystectomy syndrome, post-cholecystectomy choledocholithiasis [24].
Active Recall - Complications of Gallbladder Cancer
References
[1] Senior notes: felixlai.md (Gallbladder cancer — Overview, Treatment, and Prognosis sections, pages 563–571) [3] Senior notes: maxim.md (Cholecystectomy — Indications, approach, and complications) [8] Lecture slides: WCS 056 - Painless jaundice and epigastric mass - by Prof R Poon.ppt (1).pdf (p24) [10] Senior notes: felixlai.md (Malignant biliary obstruction — Treatment section, pages 503–507) [19] Senior notes: felixlai.md (Malignant biliary obstruction — Preoperative biliary drainage, pages 505–507) [21] Senior notes: maxim.md (Cholangiocarcinoma — Palliative care, stenting, and complications) [22] Lecture slides: Malignant biliary obstruction.pdf (p24, p26) [23] Lecture slides: Malignant biliary obstruction.pdf (p29) [24] Senior notes: maxim.md (Cholecystectomy — Specific complications)
High Yield Summary
Definition: Primary malignancy of the gallbladder, ~90% adenocarcinoma, uncommon but highly fatal.
Epidemiology: Female predominance (M:F 1:2–3), peak 6th–7th decade, very rare in HK, 5-year OS < 5%, 75% have regional/distant disease at diagnosis.
Anatomy: GB sits on segments IVb/V; lacks submucosa; thin muscularis; NO serosa on hepatic side → explains rapid liver invasion. Venous drainage directly into liver. Lymphatics: cystic node → pericholedochal → hilar → peripancreatic → celiac/SMA.
Risk Factors (4P + Stones): Gallstones (95% of GBC patients), Polyps (> 1cm), Porcelain gallbladder, PSC, Pancreatobiliary duct anomaly; also chronic cholecystitis, Mirizzi syndrome, choledochal cysts, obesity, DM, Clonorchis sinensis.
Pathophysiology: Chronic inflammation → hyperplasia → metaplasia → dysplasia → carcinoma (15–20 year sequence).
Clinical Features:
- Early: Biliary colic, RUQ pain (mimics gallstones — GBC hides behind gallstone symptoms)
- Late: Obstructive jaundice, palpable mass, constitutional symptoms (LOW/LOA), dark urine, pale stools, pruritus, ascites
- Most GBC diagnosed incidentally at cholecystectomy or at advanced stage
TNM Key Points: T1a = lamina propria; T1b = muscularis; T2a = peritoneal side; T2b = hepatic side (worse); T3 = serosa/liver/adjacent organs; T4 = major vessels/≥2 organs. N1 = 1–3 nodes; N2 = ≥4 nodes.
High Yield Summary — Differential Diagnosis
Two presentation-based frameworks:
- Early (RUQ pain/biliary colic): DDx is benign gallbladder disease — acute/chronic cholecystitis, cholelithiasis, benign polyps, Mirizzi syndrome, xanthogranulomatous cholecystitis, adenomyomatosis
- Late (obstructive jaundice/mass): DDx is malignant biliary obstruction — CA gallbladder, cholangiocarcinoma (including Klatskin tumour), CA head of pancreas, periampullary CA, CA duodenum, HCC, lymphoma, porta lymphadenopathy [8][9]
Level-based approach [10]: Hilum (GBC, Klatskin, HCC, Mirizzi, porta nodes) → Mid-CBD (cholangioCA, pancreas CA) → Distal CBD (periampullary, pancreatic, choledocholithiasis)
Key distinguishing features: GBC → fibrosed GB (Courvoisier usually negative), coexisting gallstones (95%), GB wall mass/thickening on imaging. Pancreatic CA → painless progressive jaundice + Courvoisier positive + double duct sign. Cholangiocarcinoma → duct stricture + upstream dilatation.
"Painless progressive obstructive jaundice in elderly = malignant until proven otherwise" [7]
High Yield Summary — Diagnosis of GBC
No formal diagnostic criteria — diagnosis is histopathological. Most GBC is diagnosed incidentally on cholecystectomy specimens.
Physical exam: Look for jaundice, hepatomegaly, Courvoisier's sign (usually absent in GBC), signs of inoperability (Virchow's node, ascites, Sister Mary Joseph nodule, Blumer's shelf).
Bloods: Cholestatic LFT pattern (↑↑ ALP, ↑ GGT, ↑ conjugated bilirubin). Tumour markers (CA 19-9, CEA) are NOT sensitive or specific — use for serial monitoring, not diagnosis. Clotting — check and correct Vitamin K deficiency before invasive procedures.
Imaging sequence: USG (1st line) → CT T+A with contrast (staging) → MRI/MRCP (equivocal) → PET/CT (occult advanced disease) → Staging laparoscopy (before committing to laparotomy).
Biopsy: ONLY for unresectable cases. For resectable tumours, intra-op frozen section of the cystic duct margin guides the extent of surgery.
Resectability: Unresectable if liver mets, peritoneal mets, malignant ascites, major vessel encasement, para-aortic/celiac/SMA LN involvement, or extensive hepatoduodenal ligament involvement.
High Yield Summary — Management of GBC
Framework: Assess patient status (good/bad) + tumour status (confined/spread) [15]
- Good + Confined → Laparotomy → Radical resection if confirmed confined
- Bad OR Spread → PTBD or endoprosthesis (Palliation)
Treat SEPSIS first [16]. Preoperative biliary drainage to bilirubin < 50 µmol/L [19].
Surgery by T-stage:
- Tis / T1a → Simple cholecystectomy (curative)
- T1b / T2 → Extended cholecystectomy (GB + liver wedge ≥ 2cm or Seg IVb/V + LN dissection)
- T3 → Extended cholecystectomy + en-bloc adjacent organ resection
- T4 → Generally unresectable
Open approach recommended (port-site recurrence risk with laparoscopic) [1][3]
Intra-op frozen section of cystic duct: Positive → bile duct resection + Roux-en-Y; Negative → LN dissection only [1]
Routine bile duct resection NOT recommended (no survival benefit, serious complications) [1]
At least 6 LNs must be harvested for proper staging [1]
Palliation: ERCP stenting (1st line) > PTBD > surgical bypass. Metallic stent preferred if confirmed inoperable [10]. Celiac plexus block for pain. Gastrojejunostomy for duodenal obstruction.
Adjuvant chemo: Capecitabine (BILCAP) for resected T2+. Palliative chemo: Gemcitabine + cisplatin ± durvalumab.
Prognosis: 5-year OS < 5% overall; median survival 6 months [1]
High Yield Summary — Complications of GBC
Disease complications: Obstructive jaundice → coagulopathy (Vit K malabsorption), malabsorption, immune dysfunction, renal failure. Biliary sepsis (cholangitis). Direct invasion → GOO (duodenum), liver failure, peritoneal carcinomatosis. Distant mets: lung, pleura, peritoneum [1].
Three causes of mortality in MBO: biliary sepsis, cancer cachexia, liver failure [23]
Surgical complications: Bile leak (cystic duct stump, duct of Luschka, liver cut surface, anastomosis). Routine bile duct resection risks bile leak and anastomotic stricture without survival benefit [1]. Post-hepatectomy liver failure. Port-site recurrence if prior laparoscopic approach.
Palliative intervention complications: Stent occlusion (sludge/ingrowth/overgrowth), stent migration [10][21]. PTBD bleeding from hepatic artery/PV puncture [10]. Pre-op drainage complications: pancreatitis 7%, cholangitis 26%, blocked stent 15% [22].
Post-cholecystectomy: Biliary leakage 0.5%, bile duct stricture, post-cholecystectomy syndrome, post-cholecystectomy choledocholithiasis [24].
Cholangiocarcinoma
Cholangiocarcinoma is a malignant neoplasm arising from the epithelial cells of the intrahepatic or extrahepatic bile ducts, often presenting with obstructive jaundice and carrying a poor prognosis.
Gallstones
Solid deposits, primarily of cholesterol or bilirubin, that form within the gallbladder and can obstruct biliary flow, causing biliary colic, cholecystitis, or other complications.